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ABSTRACT 
Michael D. Iglesia: A Genomic Approach to the Identity, Clonal Diversity, and  
Clinical Import of Tumor-infiltrating Lymphocytes in Human Cancers 
(Under the direction of Charles M. Perou) 
 
Immune infiltration in solid tumors has emerged as an important aspect of cancer biology. In 
particular, the presence of tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment is 
associated with improved outcomes and response to treatment in a wide variety of tumor types. These 
beneficial TIL infiltrates, comprising both B-cells and T-cells, may represent the successful targeting of 
tumor-associated antigens by the immune system leading to direct tumor cell killing. The success of 
immune checkpoint inhibitors has shown that this immune response may be manipulated to induce 
durable responses in several tumor types, and has strengthened the notion that an antigen-directed TIL 
response may occur in some cancers. However, the precise patient and tumor characteristics associated 
with these beneficial TIL responses are unclear. 
In this work, a genomic, mRNA-sequencing approach was taken to address TIL infiltration in 
diverse human tumor types, with a focus on breast cancer. Associations between signatures of TIL 
infiltration, B-cell TIL clonal diversity, genomic subtype, and other clinical correlates were identified, and 
show that significant B-cell TIL infiltrates typically represent less clonally diverse populations. 
Furthermore, in subtype-specific mouse models of breast cancer, T-cell and B-cell TIL clonal diversity are 
directly assessed through immune repertoire sequencing and a mouse model of claudin-low breast 
cancer is shown to elicit a recurrent, clonally-restricted T- and B-cell TIL response. 
This work clarifies the paradigm of conflicting immunosuppressive (pro-tumor) and anti-tumor 
immune responses within a large set of solid human tumors. B-cells within these tumors, especially, are 
shown to be an important part of the highly diverse tumor immune infiltrate, and are clonally restricted 
specifically in tumor types and subtypes associated with prognostic TILs. Immune repertoire sequencing 
of T- and B-cell TILs in mouse models of breast cancer establishes a mouse model of the claudin-low 
iv 
 
breast cancer subtype as a consistent model of a clonally-restricted, potentially antigen-directed TIL 
response within the tumor microenvironment. These findings complement the results of human clinical 
trials of immune checkpoint inhibitors and reiterate the importance of the immune system in solid tumor 
biology and patient outcomes. 
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CHAPTER 1 – INTRODUCTION  
Breast Cancer Subtypes 
Human breast cancer is now understood as a multitude of diseases rather than as one disease 
entity. These groups, or subtypes, of breast cancer vary widely in almost every regard: by morphology, 
response to treatment, clinical outcome, potential for angiogenesis and metastasis, mutational load and 
spectrum, DNA copy number, and biological pathways driving tumor development. These breast cancer 
subtypes were identified through analysis of global gene expression patterns, which defined at least five 
subtypes: luminal A, luminal B, HER2-enriched, basal-like, and claudin-low, as well as a normal-like group 
(2-6). Of these subtypes, the basal-like group has been the focus of extensive research due to its high 
rate of relapse, poor overall survival, and large degree of overlap with the “triple-negative” class of breast 
tumors (7, 8). Clinically triple-negative breast tumors are defined by the lack of expression of the estrogen 
receptor, progesterone receptor, and HER2, and thus therapies targeting these molecules and their 
related pathways are not useful for patients with triple-negative tumors (9). Due to the lack of good drug 
targets and the high rates of relapse for patients with basal-like breast cancer, this disease presents a 
unique opportunity for novel therapeutic approaches in breast cancer. 
Tumor-infiltrating Lymphocytes in Breast Cancer 
Many breast tumors have been observed to contain large numbers of tumor-infiltrating immune 
cells. Most work in this field has focused on tumor-infiltrating lymphocytes (TILs), the presence of which is 
associated with improved prognosis in many solid epithelial tumors (10-14). Like many other clinical and 
biological features, the presence of TILs, as well as tumor-associated macrophages (TAMs) and other 
tumor-infiltrating immune cells is distinct between breast tumor subtypes (1, 15-17). In particular, basal-
like breast tumors are most strongly associated with a dense immune infiltrate, although HER2-enriched 
and claudin-low breast cancers have also been associated with the presence of TILs. Interestingly, the 
association between prevalence of TILs and improved prognosis appears to be largely confined to the 
basal-like subtype of breast cancer (1, 14, 16). A more thorough understanding of this tumor-associated 
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immune infiltrate and its prognostic impact may be instrumental in bringing about new therapies for this 
clinically challenging tumor subtype. 
Breast Cancer Immune Infiltration: CD8
+
 T-Cells 
The component of the breast tumor immune infiltrate that is most intuitively promising is the CD8
+
 
subset of T-cell TILs. Several studies have shown that breast tumor infiltrates are phenotypically diverse, 
but that CD8
+
 TILs are often the most abundant TIL type (18-20). Furthermore, CD8
+
 T-cells have 
specifically been shown to be associated with improved breast cancer prognosis, again highlighting 
basal-like breast cancer as the subtype where this association is most clearly observed (13, 14, 21). It is 
appealing and intuitive to imagine that many CD8
+
 T-cell TILs are functioning as cytotoxic effectors 
targeting tumor cells. Recent work has shown that tumors with greater cytolytic activity are associated 
with a greater mutational load, expression of tumor necrosis genes and endogenous retroviruses, and 
mutations in antigen-presenting and innate immune sensing, which bolsters the idea that CD8
+
 TILs may 
be directly attacking tumor cells in an antigen-specific manner (22). It is important to note that analysis of 
CD8
+
 cytotoxic T-cells may be complicated by the presence of natural killer (NK) cells, which may also 
express a rearranged T-cell receptor (TCR) and contribute to direct cell killing by cytolytic granule release 
(23). NK cells are not as well understood in breast cancer as CD8
+
 T-cells, but tumor-infiltrating NK cells 
are present in breast cancer and have been implicated in contributing to the anti-tumor immune response 
(24, 25). 
Breast Cancer Immune Infiltration: CD4 
+
 T-Cells 
While CD8
+
 T-cells certainly play a large role in the breast cancer-associated immune response, 
CD4
+
 T “helper” cells are likely to also be important. It has been shown that CD8
+
 T-cells in the tumor 
microenvironment do not function properly in the absence of adequate CD4
+
 cells (26, 27). The 
polarization of CD4
+
 T helper cells is important for understanding their role in the tumor 
microenvironment, with IFN-γ-producing Th1 cells acting together with CD8
+
 T-cells, mature dendritic 
cells, M1 macrophages, NK cells, B-cells, and plasma cells in the anti-tumor response, while Th2 cells 
producing IL-4 and IL-5 act alongside regulatory T-cells (Treg), regulatory B-cells (Breg), M2 macrophages, 
and immature dendritic cells in the pro-tumor inflammatory response (28-30). Th17 cells represent a 
further subset of CD4
+
 T helper cells and are much more poorly understood in the tumor 
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microenvironment, both in breast cancer and in other tumor types. Current research suggests that both 
pro-tumor and anti-tumor subsets of Th17 TILs may exist, and furthermore that Th17 TILs may retain the 
ability to differentiate into either Th1 cells or Treg (31, 32). 
Breast Cancer Immune Infiltration: Regulatory T-Cells 
Regulatory T-cells, or Treg, represent in some ways the opposite end of the TIL spectrum from 
CD8
+
 T-cells. Prevalence of CD4
+
CD25
+
FOXP3
+
 Treg in breast tumors is correlated with worse prognosis, 
and has been shown to decrease the proliferation, cytolytic granule production, and cell killing of tumor-
infiltrating CD8
+
 T-cells (30, 33). Thus, Treg play an important, and potentially dominant, role in inhibiting 
anti-tumor immunity. As Treg act to suppress the anti-tumor immune response, it seems likely that Treg are 
actively recruited by the tumor. Indeed, current work suggests that Treg are recruited to breast tumors via 
a CCR4/CCL22 interaction, and that within the tumor they are activated, potentially by exposure to tumor-
associated antigens (30). In addition to inhibiting CD8
+
 TIL function, Treg may directly inhibit naïve T-cells, 
and are also known to decrease the ability of antigen-presenting cells (APCs) to present tumor antigens 
by downregulating the costimulatory molecules CD80 and CD86 (34). The full mechanisms by which Treg 
contribute to the immunosuppressive tumor microenvironment, both in breast cancer and other tumor 
types, is not fully understood. 
Breast Cancer Immune Infiltration: B-Cells 
While T-cell TILs have been the most extensively studied and are likely a very influential 
component of the tumor immune response, B-cell TILs are also present and active within breast tumors. 
B-cell TILs may compose up to 40% of the tumor immune infiltrate in some tumors, and have been 
estimated as being present in about 25% of breast tumors (35-37). Several closely related TIL 
phenotypes in the B-cell lineage have been observed in breast cancer, but very little work has been done 
to carefully differentiate their roles. For this reason, for the remainder of this manuscript, we use the term 
“B-cell TIL” to refer to any TIL in the B-cell lineage, including B-cell, plasma cell, and plasmablast TILs. 
Several groups have used gene expression profiling to show that gene signatures representing B-cell 
TILs and/or immunoglobulin expression predict improved outcomes in multiple subtypes of breast cancer 
(15, 16, 38-40). Analysis of B-cell TILs by immunohistochemistry (IHC) has again highlighted them as an 
independent prognostic feature in breast cancer (41). However, it is not entirely clear what role these B-
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cell TILs are playing within the breast tumor microenvironment. One possibility is that B-cell TILs are 
mediating a direct, antigen-specific anti-tumor immune response via production of antibodies against 
tumor-associated antigens. At least some of the cytotoxic activity of the anti-HER2 monoclonal antibody 
trastuzumab is mediated through antibody-dependent cellular cytotoxicity (ADCC), lending credence to 
the idea that naturally arising anti-tumor antibodies may also constitute an effective anti-tumor response 
(42-45). Indeed, several studies have identified auto-antibodies from patients with breast cancer, 
including antibodies against TP53 and improperly processed β-actin; however, no clear association 
between specific auto-antibodies and patient outcomes has been established (35, 46-51). However, 
several studies of small numbers of breast cancers have demonstrated B-cell TILs that are clonally 
expanded and have undergone class switching and somatic hypermutation, evidence of activation 
through antigen binding (46, 47, 52-55). Previous work by our group has also identified that high 
expression of immunoglobulin genes in basal-like and HER2-enriched breast cancer is associated with 
reduced antibody sequence diversity, further suggesting an oligoclonal anti-tumor antibody response (1). 
However, B-cell TILs may also serve primarily to potentiate the anti-tumor T-cell response. B-cell TILs 
may differentiate into either effector or regulatory B-cells, which in turn either potentiate or inhibit CD4
+
 T 
helper cell immune responses (56). Additionally, B-cells may present antigens to both CD4
+
 and CD8
+
 T-
cells, making it possible that B-cell TILs function as local APCs (57, 58). 
Breast Cancer Immune Infiltration: Tumor-associated Macrophages and Myeloid-derived Suppressor 
Cells 
While TILs have garnered attention as important contributors to the tumor immune 
microenvironment, tumor-associated macrophages and other myeloid-derived cells are also critical in 
shaping the immune milieu in breast cancer and other solid tumors. TAMs are prevalent in many breast 
tumors (59). Like T helper TILs, cytokine signaling leads to polarization of TAMs into an anti-tumor M1 
phenotype that promotes the Th1 effector response or a pro-tumor M2 phenotype associated with 
metastasis, angiogenesis, and an inflammatory wound-healing response (60-63). As part of the 
immunosuppressive microenvironment cultivated by breast tumors and other tumor types, TAMs are 
largely polarized to the M2 phenotype (60, 64). In this role, TAMs in breast cancer contribute to 
angiogenesis, invasion, and metastasis through expression of signaling molecules like VEGF, EGF, and 
matrix metalloproteinases (60, 65-69). Furthermore, distant macrophages in the lung have been shown to 
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prepare tissue microenvironment for seeding by breast cancer cells, further contributing to metastatic 
potential (70, 71). Aside from TAMs, myeloid-derived suppressor cells (MDSCs) represent a distinct 
myeloid-derived subset that plays a major role in breast tumor immune infiltration. MDSCs can act 
through several immunosuppressive mechanisms, including secretion of inflammatory pro-Th2 cytokines, 
sequestration of arginine and cysteine, and generation of reactive oxygen species and nitric oxide(72, 
73). Production of reactive oxygen species by MDSCs impairs CD8
+
 T-cell antigen recognition; MDSCs 
may also prevent antigen recognition by nitration of the TCR, which prevents MHC complex binding (72, 
74-76). In one study of women with HER2
-
 stage II-III breast cancer, patients with fewer MDSCs detected 
in peripheral blood at baseline and prior to the last cycle of chemotherapy were more likely to achieve 
pathologic complete response to chemotherapy, further supporting the role of MDSCs in tumor 
progression (77). 
Tumor Immune Infiltration in Other Solid Tumor Types 
The role of the immune system in breast cancer is similar to the role various tumor-infiltrating 
immune cells play in a wide spectrum of solid tumor types. The picture emerging from studies of tumor 
immune infiltration in diverse tumor types and subtypes is that some tumor types are highly immunogenic 
and are infiltrated with CD8
+
 and Th1 T-cells, NK cells, B-cells, and/or M1 macrophages that correlate 
with improved clinical course, but these anti-tumor immune responses generally do not lead to 
spontaneous tumor regression due to immunosuppressive signals from tumor cells, Th2 TILs, regulatory 
T- and B-cell TILs, M2 TAMs, and MDSCs. Tumor types including melanoma, non-small cell lung cancer, 
renal cell carcinoma, ovarian cancer, bladder cancer, head and neck cancer, and others have 
demonstrated this paradigm of conflicting pro- and anti-tumor immune responses (64, 78-85). There are 
variations between tumor types in the level and makeup of pro-tumor and anti-tumor immune infiltration: 
in melanoma, spontaneous tumor regression has been documented, whereas in other tumor types 
including many renal cell carcinomas, immunosuppressive MDSCs and regulatory B-cells dominate and 
minimize the role of effector immune cells (79, 86, 87).  
Immune Checkpoint Inhibitors as Cancer Immunotherapy 
The existence of this balance of endogenous pro-tumor and anti-tumor immune responses may 
be leveraged through the use of immune checkpoint inhibitors. Ipilumumab, a monoclonal anti-CTLA-4 
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antibody and the first immune checkpoint inhibitor approved for use in cancer, has shown impressive 
efficacy in unresectable or metastatic melanoma: a pooled retrospective analysis of trials demonstrated a 
3-year survival of 22% in such cases, including many heavily pre-treated patients (88). CTLA-4 works by 
a number of mechanisms to inhibit effector T-cells; among these, it inhibits signaling through the TCR by 
outcompeting the co-stimulatory molecule CD28 for its usual binding partner B27 and also induces cell 
cycle arrest in T-cells (89-93). Both ipilumumab and tremelimumab, another anti-CTLA-4 monoclonal 
antibody, have shown durable responses in a subset of patients (94-96). Other successful immune 
checkpoint inhibitors target the PD-1/PDL-1 axis, with nivolumab and pembrolizumab both being anti-PD-
1 monoclonal antibodies. PD-1 is expressed on mature T-cells following activation and in tumors is 
believed to primarily act on T-cells during the effector phase, later than CTLA-4 (97, 98). In addition, PD-1 
is expressed on a variety of immune cell types, including B-cells and NK cells, and effects on those cell 
types may contribute to its function in cancer (97, 99). PD-1 acts by binding two different ligands, PDL-1 
and PDL-2. Surface expression of PDL-1 has been observed in a variety of cell types, including T-cells, 
B-cells, endothelial cells, pancreatic islet cells, and keratinocytes, and is also highly expressed in many 
tumor types (98). PDL-2 is primarily expressed on APCs, including macrophages, mast cells, dendritic 
cells, and B-cells (98). PD-1 binds to either PDL-1 or PDL-2 as a costimulatory molecule upon binding of 
the TCR to antigen loaded on the major histocompatibility complex (MHC), and subsequently sends 
downstream signals within the T-cell to inhibit T-cell proliferation, cytokine production, and cytolytic 
function, and to impair T-cell survival (100). Thus, PD-1 contributes to effector T-cell exhaustion; this role 
has been observed both in chronic viral infection and in the tumor microenvironment (100). Interestingly, 
PD-1 signaling in Treg leads to improved immunosuppressive activity in those Treg, furthering the inhibition 
of effector T-cell responses (100). Nivolumab and pembrolizumab bind and inhibit PD-1 and have been 
used in a variety of tumor types, including advanced melanoma, non-small cell lung cancer, and renal cell 
carcinoma, and are able to induce durable responses in these tumor types (101-103). In addition to anti-
PD-1 antibodies, several monoclonal antibodies targeting PDL-1 are currently in trial for a variety of 
malignancies. Early results show that one of these, MPDL3280A, has efficacy in a variety of tumor types, 
and in bladder cancer it has been demonstrated to elicit rapid clinical response (104, 105). One phase I 
study has shown that combining ipilumumab and nivolumab in patients with melanoma improves survival 
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and induces the durable responses that are now understood to be characteristic of immune checkpoint 
inhibition (106, 107). Further research into immune checkpoint inhibitors is needed to examine 
combinations with cytotoxic chemotherapy, kinase inhibitors, and radiotherapy, as well as to expand trials 
to greater numbers of patients in a wide variety of potentially immunogenic tumor types. 
Predicting Immunogenicity in Tumors 
 The success of immune therapies across many cancer types has led to greater interest in the 
common features that distinguish immunogenic tumors. Because immunogenic tumors are often 
characterized by a dense lymphocytic infiltrate that improves survival, the notion that tumor-associated 
antigens drive the development of the anti-tumor immune response is appealing. Several potential 
sources of tumor antigens have been proposed, including mutations in existing genes (such as TP53), 
gene products overexpressed in cancer (such as HER2), viral peptides (such as HPV genes), and the so-
called cancer-testis antigens normally expressed only in immune-privileged sites (such as MAGE) (22). 
Several studies have identified peptides in one or more of these categories that may be acting as tumor 
antigens (108-113). If the immune response associated with improved survival in many cancer types is 
driven by T-cell and/or B-cell binding to tumor-associated antigens, this holds promise for cancer 
therapeutic strategies aimed not only at potentiating the existing immune response, but also at direct 
targeting of tumor-associated antigens. Because lymphocytes binding antigen through the TCR or B-cell 
receptor (BCR) subsequently undergo clonal expansion, the question of the antigen-directedness of TILs 
may be addressed by assessing the clonal diversity of TILs: in a tumor-associated antigen-driven 
response, the TIL population is expected to be clonally restricted, with one or more dominant clones able 
to bind antigens. Historically, the extreme level of diversity generated by TCR and BCR sequences has 
prevented thorough study of lymphocyte population clonality (114). However, recent advances in next 
generation sequencing have led to the development of immune repertoire sequencing, a collection of 
related methods for direct next-generation sequencing of recombined BCR and TCR chains (115, 116). 
Initial repertoire sequencing studies in cancer have shown clonal expansion of public TCR sequences in 
Treg in the TC-1 murine tumor model, as well as nonspecific T-cell proliferation leading to an expanded 
TCR repertoire in human melanoma patients treated with tremelimumab (117, 118). As tumor 
immunotherapy gains footing and the search for targetable tumor antigens becomes more feasible, it will 
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become imperative that methods of immune repertoire sequencing continue to advance and become 
standardized. In this dissertation, we address the pressing questions of tumor antigens and the role of B-
cell and T-cell clonal diversity as a means of further clarifying the role of anti-tumor adaptive immune 
responses in humans and mice.  
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CHAPTER 2 – PROGNOSTIC B-CELL SIGNATURES USING mRNA-Seq IN PATIENTS WITH 
SUBTYPE-SPECIFIC BREAST AND OVARIAN CANCER 
 
Introduction 
The role of tumor-infiltrating lymphocytes (TILs) in breast cancer is not fully understood, although 
multiple studies have shown an association between the presence of TILs and an improved prognosis 
(10-14). TILs in breast tumors are predominantly cytotoxic (CD8
+
) T-cells, and the proportion of CD8
+
 T-
cells may be prognostic (13, 14, 19, 119, 120). In contrast, TILs of the regulatory T-cell phenotype 
(CD4
+
CD25
+
FoxP3
+
 Treg) are associated with poorer outcomes in breast cancer (121, 122). The role of B-
cell TILs in human breast cancer is not as clear as that of T-cell TILs. Using gene expression profiling, our 
group and others have shown that gene signatures representing B-cells, plasmablasts, plasma cells and 
immunoglobulin predicted favorable clinical outcome in ER
+
 and ER
-
 breast tumors(15, 16, 38-40). In this 
manuscript, these are referred to as B-cell signatures; while plasmablasts and plasma cells are known to 
infiltrate some breast tumors, we use the term “B-cell TIL” here to refer to any TIL in the B-cell lineage. 
The presence of B-cell TILs as assessed by immunohistochemistry (IHC) has also been shown to be an 
independent prognostic feature in breast cancer (41). Studies of small numbers of breast tumors have 
shown the B-cell response in these tumors to be clonally expanded, with evidence of having undergone 
class switching and somatic hypermutation (46, 47, 52-55). This strongly suggested that in some breast 
tumors there may be a clonally restricted, antigen-directed B-cell anti-tumor response. Several studies 
have identified auto-antibodies in breast cancer patients, including antibodies against improperly 
processed β-actin in some medullary breast cancers, although the association between such auto-
antibodies and patient survival is unclear (35, 46, 47). Together, these findings provide evidence that B-
cell TILs may be important in affecting breast cancer biology and progression. 
Human breast cancer is a heterogeneous disease, with individual tumors varying according to 
morphology, natural history, and response to therapy. Gene expression analyses have identified at least 
five distinct genomic subtypes of breast cancer: luminal A, luminal B, HER2-enriched, basal-like, and 
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claudin-low, as well as a normal-like group (2-6). The prognostic value of both T- and B-cell TILs may be 
restricted to a subset of highly immune-infiltrated breast tumors (15). Basal-like breast tumors, in 
particular, appear to have beneficial TILs (16, 123). Multiple groups have identified signatures of 
lymphocyte-related gene expression that are overrepresented in basal-like breast tumors and predict 
better survival(15, 16); in contrast, luminal A breast tumors show low levels of lymphocytic infiltrate(123).  
Comprehensive genomic profiling of multiple tumor types in TCGA has shown there is a strong 
similarity between basal-like breast cancer and serous ovarian cancer (2). These two tumor types exhibit 
a similar mutational spectrum and share many of the same driver events (i.e. TP53 loss, RB1 loss, c-MYC 
gain, etc.). Like basal-like breast cancer, many ovarian tumors are rich in TILs. Analysis of TCGA serous 
ovarian cancer gene expression identified four genomic subtypes: mesenchymal, proliferative, 
differentiated, and immunoreactive(124). The immunoreactive subtype, in particular, showed high 
expression of T-cell chemokine ligands and lymphocyte-related genes. Furthermore, a number of studies 
have shown the presence of T- and B-cell TILs is a positive prognostic feature in ovarian cancer (14, 125-
127). As in breast cancer, the precise role of B-cell TILs is less understood than that of T-cell TILs. These 
data suggest that, like basal-like breast cancer, serous ovarian cancer may be a likely candidate for 
identifying a productive anti-tumor T-cell and/or B-cell TIL response. 
If there is an effective, subtype-specific antitumor response mediated by B-cell TILs, this presents 
the possibility of subtype-specific immunogenic epitopes that could promote development of a subtype-
specific antibody response. While some studies have identified antigen-directed TIL clones in breast 
tumors (46, 47, 52, 53, 55), currently the degree to which TILs are antigen-directed is unknown. The 
development of a mature B-cell response following antigen stimulation depends on a number of 
processes that occur during the germinal center reaction, including clonal expansion and antibody class 
switching (128, 129). While in the germinal center, B-cells undergo somatic hypermutation (SHM), 
whereby mutations at BCR loci are introduced to enhance B-cell receptor (BCR) affinity. Mutations occur 
preferentially in “hot spot” nucleotide positions, particularly within the antigen-binding complementarity-
determining regions (CDRs), and they favor replacements and transitions(130). In a tumor-antigen driven 
response, the TIL population is expected to be enriched for one or more “dominant clones” exhibiting 
BCR characteristics consistent with somatic hypermutation. Here, using a novel approach to characterize 
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B-cell responses from short read mRNA-seq data, we demonstrate subtype-specific enrichment of B-cell 
gene segments in basal-like and HER2-enriched breast cancer and in immunoreactive ovarian cancer. 
We show evidence of clonal restriction of the B-cell response in these three tumor types, and mutation 
patterns consistent with SHM in basal-like and HER2-enriched breast cancer. These findings suggest an 
important role for the endogenous B-cell response specifically in these tumor subtypes. 
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Methods 
Data Sets 
The breast cancer data set used for all analyses except the survival analysis of gene expression 
signatures was the TCGA data set of 819 mRNA-seq samples, comprising 728 breast tumors and 91 
normal breast samples (see TCGA Data Portal at https://tcga-data.nci.nih.gov/tcga/, CGHub at 
https://cghub.ucsc.edu/). This 728 sample set is an extension of the 480 tumors previously profiled by 
microarray(2), but these 480 plus 350 new samples have all been assayed by mRNA-seq using Illumina 
2x50bp sequencing as described by the TCGA in an evaluation of lung squamous samples(131). Gene 
expression values were represented as RSEM (RNA-seq by Expectancy-Maximization) data normalized 
within-sample to the upper quartile of total reads as previously described (131). These data and further 
details about data processing are available at the TCGA Data portal under the V2_MapSpliceRSEM 
workflow  (https://tcga-
data.nci.nih.gov/tcgafiles/ftp_auth/distro_ftpusers/anonymous/tumor/brca/cgcc/unc.edu/illuminahiseq_rna
seqv2/rnaseqv2/unc.edu_BRCA.IlluminaHiSeq_RNASeqV2.mage-tab.1.6.0/DESCRIPTION.txt). Genomic 
subtype was assigned within the set of 728 mRNA-seq samples using the PAM50 assay (132). The 
training set of breast samples used in the PAM50 assay is 50% clinically ER
+
, therefore the mRNA-seq 
data were normalized to reflect the training set 
(https://genome.unc.edu/pubsup/breastGEO/Guide%20to%20Intrinsic%20Subtyping%209-6-10.pdf). 
Based on clinical data taken from the TCGA Data portal on September, 2012 (https://tcga-
data.nci.nih.gov/tcga/), of the 728 samples, 157 were ER
-
, 535 were ER
+
, 2 were ER-indeterminate, 29 
did not have ER status assays performed, and 5 did not have available data, indicating that 77% of the 
mRNA-seq samples were ER
+
. To normalize the data similar to the PAM50 training dataset, in which 50% 
of samples are ER
+
, all 157 ER
-
 samples were selected, as well as 157 randomly selected ER
+
 samples. 
The median gene expression for the PAM50 intrinsic gene list was calculated based on this subset of 
samples. To perform platform correction for mRNA-seq, these median values were then subtracted from 
all 728 samples prior to running the PAM50 assay as previously described(132) 
(https://genome.unc.edu/pubsup/breastGEO/PAM50.zip). Due to the short median follow-up time (17 
months) of the TCGA data set, survival analysis of gene expression signatures were carried out using a 
㡠ҫ
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microarray-based gene expression data set of 855 breast tumors with published intrinsic subtype calls 
(140 basal-like, 90 claudin-low, 144 HER2-enriched, 243 luminal A, 162 luminal B, 76 normal-like) and 
clinical data (combined data from the following data sets: GSE2034, GSE12276, GSE2603, and the 
NKI295 (microarray-pubs.stanford.edu/wound_NKI/Clinical_Data_Supplement.xls)) (133). Survival 
analyses of BCR segment expression, however, used the TCGA mRNA-seq data set. For all analyses of 
ovarian cancer, we used the TCGA serous ovarian cancer mRNA-seq data set, which, like the breast 
cancer data set, represents new mRNA-seq data, again using Illumina 2 x 50bp sequencing, on a subset 
of the 500 cases from the TCGA ovarian project (124). This mRNA-seq data set consists of 266 tumors 
with follow-up data (https://tcga-data.nci.nih.gov/tcga/, https://cghub.ucsc.edu/). 
Gene Expression Signatures and Survival Analyses 
Immune gene expression signatures were established using unsupervised hierarchical clustering 
of mRNA-seq expression data for 728 breast tumor samples. Gene dendrogram nodes corresponding to 
genes characteristically expressed in specific immune cell types were identified and validated through 
DAVID functional annotation clustering and IPA (Ingenuity®Systems, www.ingenuity.com)(134, 135). 
Gene lists for all five signatures are included in Appendix 1. Additional lymphocyte gene signatures were 
obtained from published studies: IGG_Cluster(38), B_Cell(136), and B_Cell_60gene(39) are B-cell 
signatures, and T_Cell(136), CD8(136), LCK(137), and TNBC_T-Cell(16) are T-cell signatures, with the 
CD8 signature specifically representing CD8
+
 T-cells. 
Survival analyses were performed by Kaplan-Meier analysis and log-rank testing, and hazard 
ratios were derived from the Cox proportional hazards model. For analysis of the prognostic value of BCR 
segment expression, samples were divided into high and low expression groups of equal number for 
Kaplan-Meier analysis and log-rank testing. To evaluate the prognostic value of gene expression 
signatures, the Cox proportional hazards model was used with each signature tested as a continuous 
variable. Multivariate Cox proportional hazards models were used to test the prognostic value of 
individual gene expression signatures when combined with the other clinical and genomic variables. 
To provide a control for the number of prognostic BCR gene segments, 353 (the number of BCR 
gene segments tested) random genes were selected and p values were calculated for the association of 
each of these genes with overall survival (breast) or progression-free survival (ovarian) as in the BCR 
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gene segments. The number of significant (p < 0.05) p values was calculated from this set and 95% 
confidence intervals were calculated through bootstrap resampling. 
B-Cell Receptor Diversity 
The method for estimating sequence diversity of a BCR gene segment for an individual 
sample/tumor using paired-end mRNA-seq data is outlined in Figure 2.7. Read pairs mapping to the 
EntrezGene genomic location (www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene)(138) of a given BCR 
gene segment were identified (mapped by MapSplice(139)). The sequence of these read pairs was 
compared to the hg19 reference genome to identify non-reference bases. The genomic position and 
nucleotide identity of all non-reference bases was identified for each read pair. Each observed pattern of 
non-reference bases was then assigned a score representing the number of read-pairs containing exactly 
that pattern of non-reference bases. This set of observed patterns and their corresponding count was 
used to calculate the effective number of species, which is a diversity function isomorphic to Shannon 
entropy, as described by Jost et al.(140) . 
De novo Assembly and Somatic Hypermutation Analysis 
De novo assembly of BCR variable (V) gene segments from paired-end mRNA-seq reads was 
performed using the Assembly-Based Re-Aligner (ABRA) algorithm (Mose et al., manuscript in 
preparation). To generate ABRA contigs, unmapped reads and reads mapping to a BCR variable region 
of interest were first split into overlapping k-mers where k=31. K-mers that were comprised exclusively of 
non-ambiguous bases with quality score > 20 were assembled into a de Bruijn graph. K-mers with fewer 
than 100 observations were then pruned from the graph. The graph was then traversed to produce all 
possible contigs. This set of contigs was used for somatic hypermutation analyses. 
To determine if the sequence of a BCR variable gene segment was consistent with somatic 
hypermutation, the reference sequence for that gene segment was first established by Smith-Waterman 
alignment to each IMGT® (IMGT®, the international ImMunoGeneTics information system® 
http://www.imgt.org (founder and director: Marie-Paule Lefranc, Montpellier, France))(141-147) reference 
allele sharing the same gene segment family and selection of the closest match. The segment sequence 
was compared to the reference sequence, and mutated and non-mutated bases were counted within 
SHM hotspots (WRCY, RGYW, WA, and TW sequences) and non-hotspot regions(148). Mutated and 
㡠ҫ
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non-mutated (i.e., reference and non-reference) bases were counted again within CDRs. Chi-square 
testing was used to determine if the distribution of mutated bases was consistent with the mutation 
pattern expected in SHM; chi-square testing was conducted separately for the whole V segment 
sequence and for CDRs. 
The method for producing an overall estimate of the degree of somatic hypermutation for a BCR 
variable segment in mRNA-seq data is outlined in Figure 2.9. ABRA contigs were first constructed for that 
V gene segment and quantitated by BWA paired-end alignment(149) of all unmapped reads and reads 
mapping to that segment to the set of ABRA contigs. Multiple mappings were allowed, as long as both 
read pairs mapped to the same contig. For each contig, the number of SHM hotspot mutations, SHM 
hotspot non-mutated bases, non-hotspot mutations, and non-hotspot non-mutated bases were counted 
for the whole segment and within CDRs. This information was weighted by the BWA alignment score for 
that contig. These weighted values were summed across all contigs and chi-squared testing was used to 
determine if the mutation pattern across the whole segment or within CDRs indicated the presence of 
SHM. For this analysis, only segments with a number of mapped reads greater than or equal to 0.04 × the 
length in bp of the segment (approximating even coverage of depth 2) were considered for sequence 
analysis in a given sample. 
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Results 
B-cell gene expression signatures are prognostic in breast and ovarian cancer.  
Increased expression of B-cell gene signatures has been shown to be favorably prognostic in 
breast cancer (38-40). To explore the role of B-cells and other lymphocyte cell types in the different 
intrinsic subtypes of breast cancer, immune cell associated genomic signatures were newly derived from 
unsupervised clustering of mRNA-seq data from 728 TCGA breast cancer samples (Figure 2.1A). Gene 
dendrogram nodes containing characteristic lymphocyte genes were selected as potential gene 
signatures. The identities of these signatures were confirmed through functional annotation analysis and 
gene pathway-based analysis (134, 135). These and other previously published lymphocyte gene 
signatures were used to confirm the prognostic value of TILs on a genomic level, and to assess whether 
this benefit is isolated to one or more intrinsic subtypes. We first evaluated a gene expression microarray 
data set of 855 breast tumors, using a univariate Cox proportional hazards model, for prognostic value by 
subtype of lymphocyte gene signatures(133). For the newly derived B_Cell_cluster signature derived from 
unsupervised clustering here, the IGG_cluster previously developed by our group(38), and three B-cell 
gene signatures generated by others(15, 16, 39), overall expression in breast tumors was greater in the 
basal-like and HER2-enriched subtypes (Figure2. 2 A,C). Similar to previous work (39, 41, 150), high 
expression was associated with better metastasis-free survival in basal-like and HER2-enriched tumors 
with greatest difference in hazards in the basal-like subtype (Table 2.1).  
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Figure 2.1 A Concordant expression of genes from different immune cell types in a distinct 
subset of primarily basal-like, HER2-enriched, and normal-like tumors. Unsupervised hierarchical 
clustering of breast cancer mRNA-seq data (n=728); signatures B_Cell_cluster, CD8_cluster, 
T_Cell_cluster, CD68_cluster, and MacTh1_cluster are derived from this hierarchical clustering. B 
Expression of breast cancer-derived gene expression signatures in an ovarian cancer mRNA-seq data 
set (n=266). 
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Figure 2.2 Box plots of expression of IGG_Cluster and CD8 gene expression signatures by 
subtype, with one-way ANOVA p value, in A, B microarray data from 855 breast tumors C, D mRNA-
seq data from 819 breast samples (728 tumor, 91 normal breast) and 266 ovarian tumors E, F mRNA-
seq data from 266 ovarian tumors. Expression of immune genes is high in basal-like, claudin-low, and 
HER2-enriched breast cancer subtypes and the immunoreactive ovarian cancer subtype. 
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We next performed a similar analysis on TCGA ovarian cancer data. Overall B-cell gene 
signature expression was increased in immunoreactive ovarian tumors (Figure 2.2E-F). Several B-cell 
gene signatures were prognostic for progression-free survival in the immunoreactive ovarian tumor 
subtype, which was not true for the other subtypes (Table 2.1). T-cell signatures (15, 16, 137) were also 
evaluated, and showed a similar pattern of expression and prognostic value (Fig 2B, D). In multivariate 
survival analysis of individual immune signatures with other clinical and genomic features in breast 
cancer, most B-cell and T-cell signatures remained significantly prognostic (Table 2.2).  
For both breast and ovarian tumors, B-cell gene signature expression strongly correlated with 
other lymphocyte gene signatures, including those representing T-cells and macrophages (Figure 2.3). 
Likelihood ratio testing was performed to assess the independence of immune gene signatures as 
predictors of survival. Conditioning on clinical variables (node status, age, and hormone receptor status 
for breast; stage, grade, and age for ovarian) and adding either B-cell or T-cell gene signatures to the 
model, only one gene signature was needed to significantly improve the predictive power of the model 
(data not shown). In accordance with the high degree of correlation between immune cell signatures, 
adding further signatures for the same cell type did not improve the model. Each ordering of immune 
signatures was tested to ensure this finding was not specific to specific signatures. Including both B-cell 
and T-cell signatures in the model, in breast cancer only one signature significantly improved the model; 
in ovarian, one B-cell signature and one T-cell signature each significantly improved the model. Together, 
these analyses indicate an improved outcome for patients with specific subtypes of breast and ovarian 
cancer. This correlated with the presence of B-cells, plasmablasts and/or plasma cells in the tumor 
microenvironment, which suggests a productive endogenous B/plasma cell response may be present in 
the tumor microenvironment. 
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Figure 2.3 Signatures of lymphocyte infiltration in breast tumors are highly 
correlated in A an mRNA-seq expression data set of 728 breast tumors and 91 
normal breast samples B an mRNA-seq expression data set of 266 ovarian tumors. 
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Specific B-cell receptor gene segment expression is prognostic in basal-like breast cancer.  
Next, we wished to determine if the B-cell gene signature found in patients with basal-like breast 
cancer was consistent with an antigen-specific response. Other groups have shown clonal expansion and 
somatic hypermutation in breast B-cell TILs, suggesting an antigen-directed response in those samples 
(46, 52, 55). Actively responding antigen-specific B-cell populations are characterized by clonal 
expansion; thus, we expect B-cell clonal expansion in patients where an effective, antigen-directed anti-
tumor response is occurring. Because the clonal diversity of a B-cell population can be inferred by the 
diversity of the BCRs they express, there should be a prognostic benefit in samples with increased 
expression of specific BCR gene segments (i.e. immunoglobulin heavy chain and light chain variable, 
joining, diversity, and constant region segments). It has been shown that the BCR protein from breast 
cancer TILs is mainly produced by plasma cells, not B-cells (40). Here, we will continue to use the term 
“B-cell” to refer to the heterogeneous group of BCR-producing cells in the B-cell lineage.  
We first calculated the expression levels of all 353 BCR gene segments available in the IMGT® 
database across the breast and ovarian tumor data. Breast HER2-enriched and basal-like tumors, as well 
as ovarian immunoreactive and mesenchymal tumors, showed high expression widely across BCR 
segments (Figure 2.4). We analyzed prognosis by expression of each individual BCR segment, and then 
compared this to an identical number of randomly selected genes using a bootstrap procedure to assess 
the significance of this finding. In basal-like breast tumor subtypes, we identified a significantly greater 
number of BCR segments predictive of overall survival than expected by random sampling (Figure 2.5A-
B). No other breast cancer subtype demonstrated a greater number of prognostic BCR segments than 
expected by chance (Figure 2.5A). Similarly, in patients with ovarian cancer significantly more BCR 
segments were predictive of progression-free survival in immunoreactive tumors than in the other 
subtypes (Figure 2.5C-D). The mesenchymal and differentiated ovarian subtypes also showed 
significantly more prognostic BCR segments than expected by chance. In breast tumors, this finding 
cannot be explained solely by increased overall expression of BCR gene segments in the basal-like 
subtype, as the highest expression of BCR segments was found in the HER2-enriched subtype (Figure 
2.4). Prognostic segments were discovered in multiple gene families including IgHV, IgHJ, IgHC, IgKV, 
IgKJ, IgKC, IgLV, IgLJ, and IgLC. IgKC, which has been previously identified as prognostic in several 
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solid tumor types including breast cancer (40), predicted progression-free survival in ovarian cancer but 
did not attain significance in the breast data set. Individual representative plots of overall or progression-
free survival by high vs. low expression of representative prognostic segments are shown in Figure 2.6.  
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Figure 2.4 Expression level of all BCR segments across breast cancer subtypes and ovarian 
cancer. Expression is highest in basal-like and HER2-enriched breast cancer and immunoreactive 
ovarian cancer subtypes and highly correlated within groups. 
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Figure 2.5 Expression level of BCR segments is preferentially predictive of improved overall 
survival in basal-like breast cancer and progression-free survival in immunoreactive ovarian cancer. A, 
C Grid of prognostic value of all BCR segments (colored cells represent positively prognostic 
segments). B, D Prognostic BCR segment distribution across subtypes, with bootstrap confidence 
intervals (95%). Control value represents 353 random non-BCR genes. 
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Figure 2.6 Kaplan-Meier plots, with log-rank p value, of overall or progression-free survival in 
TCGA breast basal-like and ovarian immunoreactive cancer, respectively. Samples are stratified by 
expression of representative BCR gene segments IGHV4-39 (A, B) or IGHV1-8 (C, D). 
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Since B-cells undergo somatic hypermutation following antigen stimulation in the germinal center 
reaction, reads mapping to each germline BCR gene segment are expected to contain many 
corresponding single nucleotide variations. Each group of mapped reads corresponding to a BCR gene 
segment would then exist as a population, the diversity of which should inversely relate to the degree of 
clonal expansion in the tumor infiltrate. We used the Shannon entropy index normalized as the effective 
number of species as a measure of diversity(140) . For this analysis, we calculated the diversity per 
patient of each BCR gene segment; a description of this procedure is shown as Figure 2.7. Basal-like, 
HER2-enriched, and luminal B breast tumors, and immunoreactive ovarian tumors, include a subset of 
tumors with high expression of low-diversity segments (Figure 2.8). This finding is consistent with the 
presence of a clonally-expanded B-cell population within those tumor subtypes that is absent in other 
subtypes. 
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Figure 2.7 Method of calculating BCR sequence diversity from paired-
end mRNA-seq reads mapping to BCR segment loci. 
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Figure 2.8 A Basal-like, HER2-enriched, and luminal B tumors show high expression of low-
diversity BCR V segment pools (data averaged over top ten highest expressed V segments). B 
Density of V segment expression in breast cancer. C A subset of predominantly immunoreactive 
ovarian tumors show high expression of low-diversity BCR V segment pools (data averaged over top 
ten most highly expressed V segments). D Density of V segment expression in ovarian cancer. 
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Analysis of somatic hypermutation patterns in mRNA-seq data.  
Somatic hypermutation in BCR gene segments is characterized by mutations that favor defined 
local sequence regional “hotspots” and CDRs, due to bias in the enzymatic activity that facilitates the 
mutation process(130). In order to evaluate the degree of somatic hypermutation represented in our data, 
we made use of the novel de novo assembly algorithm ABRA to assemble unique contigs from reads that 
map to each BCR variable (V) segment locus, followed by analysis of the contigs for the presence or 
absence of SHM. These contigs allowed us to analyze SHM mutation patterns across a V segment or its 
CDRs, rather than interrogating each mRNA-seq read pair separately. An overview of this method is 
given as Figure 2.9.  
We applied our method of analyzing somatic hypermutation in mRNA-seq data to the TCGA 
breast and ovarian data sets. For the top 10 most highly expressed BCR V gene segments in breast or 
ovarian tumors in our data sets, the basal-like and HER2-enriched breast subtypes were enriched for 
tumors with V gene segments consistent with SHM (Figure 2.10). Immunoreactive ovarian tumors showed 
a high proportion of segments with mutation patterns suggestive of SHM, but it was not significantly 
higher than the proportion observed in other ovarian subtypes. The presence of SHM sequence 
characteristics from TILs is suggestive of the presence of antigen-experienced B-cells, potentially against 
tumor antigens, in the tumor microenvironment.   
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Figure 2.9 Method of calculating likelihood of enrichment for somatic hypermutation from mRNA-
seq reads mapping to BCR segment loci. 
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Figure 2.10 Percent of assembled contigs significantly enriched for mutation patterns consistent 
with evidence of SHM in breast (A, B) and ovarian (C, D) tumors. Sequence characteristics were 
evaluated both for the entire contig (A, C) and for CDRs only (B, D). Values represent averages over 
the top ten most highly expressed BCR segments (error bars: ± standard deviation). 
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Discussion  
We define here four characteristics of an active, antigen-driven, anti-tumor B-cell response that 
can be identified from mRNA-seq data, namely: 1) increased expression and prognostic value of B-cell 
gene signatures, 2) increased expression and prognostic value of BCR gene segments, 3) decreased 
diversity of highly expressed BCR gene segments, and 4) mutation patterns consistent with BCR somatic 
hypermutation. All four conditions were found in basal-like breast cancers, and three of these conditions 
were found for immunoreactive ovarian tumors and HER2-enriched breast tumors. These findings support 
the hypothesis that a productive B-cell-driven endogenous anti-tumor response may be generated in 
many basal-like breast and immunoreactive ovarian carcinomas. To our knowledge this represents the 
first inference of BCR repertoire characteristics from mRNA-seq data. 
 Investigations into the anti-cancer adaptive immune response have largely been focused on T-
cells. Accordingly, current cancer immunotherapy is directed at modifying the T-cell immune response 
through modulating targets like CTLA-4 and PDL-1. In this work, we show that the presence of tumor-
infiltrating B-cells correlated with overall and progression-free survival suggesting that B-cells play an 
important role in anti-tumor immunity. We do show that the expression of B-cell genes was highly 
correlated with the expression of T-cell genes. By further demonstrating that in specific breast and 
ovarian cancer subtypes B-cell TILs are clonally expanded and enriched for somatic hypermutation, we 
provide evidence that B-cell TILs are not merely a surrogate marker for an anti-tumor T-cell response. 
While it is technically possible that previously expanded B-cell clones may be trafficked to the tumor 
independent of their antigen binding capability, previous studies showing clonal evolution within breast 
tumors make this unlikely(47, 52, 53, 55), as does the association with specific tumor subtypes. Tumor 
antigen-directed B-cell responses, which we suggest are present in many basal-like breast and 
immunoreactive ovarian tumors, may provide a novel way to clinically target these tumor types. 
Interestingly PD-1 (PDCD1), which is expressed on activated T- and B-cells, is currently a very promising 
target for immunotherapy. Previous work has shown that blocking the interaction of PD-1 with PDL-1 and 
PDL-2 (PDCD1LG2) enhances the activation, proliferation, and cytokine production of human B-cells in 
the presence of TLR stimulation(151). As immunotherapy advances in breast cancer, it will be important 
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to evaluate B-cell TILs to investigate if and how anti-cancer immunotherapies may modulate the B-cell 
compartment. 
As more immunomodulatory treatments become available for cancer therapy, one critical issue is 
the identification of the specific cancer patients who may benefit from such therapy. This work highlights 
the subtype association of clonally restricted B-cell responses. Previous studies in ovarian cancer have 
been mixed as to the importance of B-cell TILs, perhaps because of the heterogeneity of the B-cell 
response across the subtypes of ovarian cancer. Milne, et al. highlighted the high-grade serous histologic 
subtype as being selectively associated with TILs predictive of disease-specific survival (127). Here, we 
further identify the immunoreactive genomic subtype of serous ovarian cancer as containing prognostic 
TILs. Among basal-like breast tumors, it is interesting to note that patients with high B-cell infiltration as 
assessed by gene signatures were also significantly younger than other patients with basal-like breast 
cancer (data not shown), corroborating previous work highlighting this group(152). 
Other investigations of B-cell TILs in breast cancer have found the survival benefit associated 
with B-cell gene expression to be dependent on proliferation (39, 40, 150). However, we do not see this 
association in our data. While the basal-like and HER2-enriched subtypes are both highly proliferative, we 
observed no survival benefit for B-cell TILs in luminal B tumors, which are also characterized by high 
proliferation. Furthermore, likelihood ratio testing conditioning on clinical variables and genomic subtype 
(data not shown) demonstrated that proliferation did not significantly increase the predictive ability of the 
model in breast cancer. 
This work again underscores the similarity between basal-like breast and ovarian tumors. 
Previous genomic studies have established that serous ovarian tumors resemble basal-like breast cancer 
in terms of their mutational profiles and DNA copy number changes (2). Here we show that this similarity 
extends to the immune component of the tumor microenvironment. In terms of the immune response, 
basal-like breast cancer bears more similarity to ovarian immunoreactive cancer than to the luminal A 
breast cancer subtype. This adds further weight to the notion that the therapeutic approach to basal-like 
breast and ovarian cancer could be similar. 
The claudin-low subtype of breast cancer is also known to have abundant TILs(153), which we 
confirm by expression of TIL gene signatures (Figure 2.2A-B). However, unlike the basal-like and HER2-
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enriched subtypes, TIL abundance was not associated with a survival benefit within claudin-low tumors 
(Table 2.1). This could potentially be due to different immunosuppressive mechanisms within the tumor 
microenvironment, or it is possible that claudin-low tumors elicit a nonspecific inflammatory response in 
contrast with other high-immune breast tumors. We were unable to assess the BCR sequence diversity of 
claudin-low TILs as very few (fewer than ten) claudin-low tumors have been identified within the TCGA 
data set. If TILs within claudin-low tumors are not productive or antigen-directed, misclassification of 
these tumors may limit the effectiveness of immunomodulatory treatments within triple-negative breast 
cancers. 
There are several standard approaches to analyzing the adaptive immune response present in 
the tumor microenvironment and tumor-draining lymph node. Immunohistochemistry and 
immunofluorescence can be performed, although specific antibodies often require frozen tissue; similarly, 
flow cytometry can be performed on frozen tissue. One of the benefits of the approach described here is 
the potential to perform the analysis on formalin-fixed paraffin embedded tissue as methods for mRNA-
seq from these samples have been demonstrated(154), and will continue to improve and become 
standardized. As this is available on a substantially greater number of patients compared to frozen tissue, 
this approach could allow for a much larger group of patients to be analyzed for the presence of adaptive 
immune signatures. Indeed, there are a large and growing number of human tissue samples with 
available mRNA-seq data; through the methods described here, these samples may be analyzed for 
antigen-directed B-cell responses. 
Given our data that the presence of B-cells in the tumor microenvironment in patients with basal-
like and HER2-enriched breast cancers and immunoreactive ovarian cancer is predictive of outcome, the 
role that endogenous B-cells play at these sites of tumor growth is a critical question. Plasma cells could 
generate anti-tumor antibodies that could be important in the early control of the growth of breast cancer 
cells, but which may ultimately become lost during tumor progression. Alternatively, B-cells may function 
as antigen-presenting cells to activate tumor-specific T-cells, which in turn may be inhibited via 
immunosuppressive mechanisms such as the PD-1/PDL-1 interaction. Future work is needed to 
determine the mechanism by which B-cells affect tumor growth in these different molecular subtypes of 
cancer, and if and how this could be harnessed to improve endogenous anti-tumor immune responses. 
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The most difficult breast tumors to treat clinically are often of the “triple-negative” class, defined 
as such by the lack of cell-surface expression of estrogen receptor, progesterone receptor, and HER2 (9). 
The majority (60-80%) of triple-negative tumors are basal-like (7), and thus the basal-like subtype 
represents a critical target for the development of novel therapeutics. The presence of BCR 
characteristics associated with overall survival and consistent with a productive anti-tumor endogenous B-
cell response suggests that methods to enhance or induce anti-tumor B-cells in patients with basal-like 
breast cancer may be clinically efficacious. 
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CHAPTER 3 – THE PROGNOSTIC IMPACT OF TUMOR IMMUNE INFILTRATION ACROSS DIVERSE 
SOLID TUMOR TYPES 
 
Introduction 
Many solid tumors are associated with a substantial immune infiltrate. This immune infiltration 
represents a complex and important aspect of the tumor microenvironment, and may comprise many 
distinct cell types, including various phenotypes of T and B tumor-infiltrating lymphocytes (TIL), tumor-
associated macrophages (TAM), natural killer (NK) cells, and myeloid-derived suppressor cells (MDSCs). 
The complex interplay between solid tumors and the host immune system has been widely studied, but is 
in many cases still poorly understood. In a number of distinct tumor types, the presence of TILs has been 
demonstrated as an important prognostic factor (10, 78-84). For example, the presence of CD8
+
 T-cell 
TILs is a good prognostic factor in many tumor types including melanoma, colorectal, breast, ovarian, and 
non-small cell lung cancer, and in several cases it has been demonstrated that these CD8
+
 TILs are able 
to specifically kill tumor cells (155). Th1 T helper cells and B-cell TILs have also been implicated in the 
anti-tumor immune response (56, 85). Solid tumors classically are understood to cultivate an 
immunosuppressive microenvironment to combat the anti-tumor host immune response through anergy 
and exhaustion of TILs and induction of a pro-tumor, inflammatory wound-healing response (156). This is 
accomplished through cytokines such as IL-8 and IL-12 released by tumor and stromal cells, and the 
recruitment of M2 macrophages, regulatory T-cells (Treg), and MDSCs (64, 157, 158). This tumor immune 
regulatory response has been put forth as an explanation for the inability of the anti-tumor adaptive 
immune response to cause tumor regression. This is supported by studies showing that the presence of 
Treg, TAMs, and/or MDSCs predict worse outcomes in diverse tumor types including melanoma, renal cell 
carcinoma, breast, ovarian, bladder, prostate, and non-small cell lung cancer (30, 64, 157). The wide 
impact and clinical relevance of the tumor-associated immune response makes it critical to develop a 
more thorough understanding this phenomenon. 
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Next-generation sequencing and large-scale genomics have become critical to our understanding 
of human cancers. Through efforts such as The Cancer Genome Atlas (TCGA), genomic data on a wide 
variety of platforms has become available. In many tumor types these data have been used to derive 
genomic subtypes that complement previous approaches to categorizing human tumors. By combining 
diverse data types, groupings both within and across tumor types have emerged (159). This deepens our 
understanding of distinctions within tumor types, such as in the identification of a subtype of 
glioblastomas driven by methylation (i.e. G-CIMP), and also highlights significant similarities between 
previously distinct tumor types, such as in the identification of the “squamous” genomic subtype, which 
combines lung, head and neck, bladder, and some breast tumors into a single group (159, 160). 
Describing tumors along genomic lines may refine clinical practice in a way that more closely reflects 
tumor biology. 
Cancer immunotherapy has been extensively pursued as an alternative or complement to 
cytotoxic chemotherapy and radiotherapy, but has recently shown great promise in a number of tumor 
types on its own. Inhibition of the immune checkpoint proteins CTLA-4, PD-1, and PDL-1 reduces the 
ability of the tumor microenvironment to suppress the host anti-tumor immune response (94, 102, 104). 
This leads to a decrease in the functionality of Treg TILs and proliferation of CD8
+
 TILs. The immune 
checkpoint inhibitors ipilumumab (anti-CTLA-4), nivolumab and pembrolizumab (anti-PD-1), and various 
early-stage PDL-1 inhibitors such as MPDL3280A have shown clinical responses in melanoma, bladder, 
ovarian, renal cell, and non-small cell lung cancers (95, 102, 104, 105, 107). Interestingly, both nivolumab 
and ipilumimab have resulted in durable responses long after discontinuing treatment in studies involving 
melanoma, non-small cell lung cancer, and renal cell carcinoma, suggesting an ongoing anti-tumor 
immune response (101-103). As immune checkpoint inhibitors and other immune-targeted therapies gain 
ground in diverse tumor types, a key question is the identification of tumor characteristics that predict 
response to these agents. Evidence in melanoma and bladder cancer suggests that responders may 
already harbor clonally restricted, anti-tumor TILs that are able to take effect after tumor 
immunosuppression has been lifted (105, 117). In this work, we use mRNA-seq data to analyze the 
prevalence and prognostic relevance of tumor immune infiltrates, and the clonal diversity of tumor-
infiltrating B-cells, in a large number of tumors from diverse tissue types. Through comprehensive 
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analysis of tumor immune infiltrates across tumor types, we identify specific tumor types and subtypes 
enriched for immune gene expression consistent with an active, clonally restricted anti-tumor TIL 
response.  
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Methods 
Data Sets 
The data set used for all analyses comprised mRNA-seq data from 3485 TCGA tumors (see 
TCGA Data Portal at https://tcga-data.nci.nih.gov/tcga/, CGHub at https://cghub.ucsc.edu/), which was 
originally described in Hoadley, et al. 2014 with the following modifications (159). All tumor samples from 
Hoadley, et al. were used, except for 161 AML samples, which were removed. Data for 329 melanoma 
samples were added to the set. Data for all melanoma samples represent the mRNA-seq data set used in 
the TCGA melanoma manuscript (TCGA, Cell, In Press). In total, this data set includes 118 urothelial 
bladder carcinomas (BLCA), 821 breast ductal carcinomas (BRCA), 250 colorectal adenocarcinomas 
(CRC, 179 colon tumors and 71 rectal tumors), 120 glioblastoma multiforme tumors (GBM), 301 head and 
neck squamous cell carcinomas (HNSC), 461 clear cell renal cell carcinomas (KIRC), 267 lung 
adenocarcinomas (LUAD), 237 lung squamous cell carcinomas (LUSC), 240 serous ovarian 
adenocarcinomas (OV), 329 cutaneous melanomas (SKCM), and 341 uterine corpus endometrial 
carcinomas (UCEC). All samples were assayed by mRNA-seq using Illumina 2x50bp sequencing as 
described by the TCGA Research Network (131). Gene expression values were represented as RSEM 
(RNA-seq by Expectancy-Maximization) data normalized within-sample to the upper quartile of total reads 
as previously described (37). These data and further details about data processing are available at the 
TCGA Data portal under the V2_MapSpliceRSEM workflow  (https://tcga-
data.nci.nih.gov/tcgafiles/ftp_auth/distro_ftpusers/anonymous/tumor/brca/cgcc/unc.edu/illuminahiseq_rna
seqv2/rnaseqv2/unc.edu_BRCA.IlluminaHiSeq_RNASeqV2.mage-tab.1.6.0/DESCRIPTION.txt). Genomic 
subtypes within tissue types and Cluster of Clusters Assignments (COCA) subtypes were obtained from 
previous publications of those TCGA tissue types (2, 131, 160-165). No COCA subtype was assigned to 
melanoma samples, and thus melanoma was assigned to its own group in COCA subtype analyses due 
to existing data showing its distinctive features distinguishing it from the other included tumor types (166). 
Gene Signatures and Survival Analyses 
Several immune gene signatures were previously developed by unsupervised hierarchical 
clustering of mRNA-seq expression data for 728 breast tumor samples (1). In addition to these, other 
tumor-infiltrating lymphocyte and macrophage gene signatures were obtained from published studies. 
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Multiple signatures were identified for each cell type to reduce bias from individual gene lists. 
IGG_Cluster (38), B_Cell (136), B_Cells (167), B_Cell_cluster (1), B_Cell_60gene (39), and 
TNBC_B_Cell (16) are B/plasma cell signatures. T_Cell (136), T_Cells (167), T_Cell_cluster (1), CD8 
(136), CD8_cluster (1), LCK (137), and TNBC_T-Cell (16) are T-cell signatures, with the CD8 and 
CD8_cluster signatures specifically representing CD8+ T-cells. MacTh1_cluster (1), CD68_cluster (1), 
Mac_CSF1 (168), and Macrophages (167) are all macrophage/monocyte signatures. 
Univariate survival analyses were performed by Cox proportional hazards modeling with each 
signature tested as a continuous variable. Multivariable Cox proportional hazards models were used to 
evaluate the prognostic value of individual gene expression signatures when combined with tumor 
type/subtype information and clinical variables. All multivariable survival analyses included one gene 
expression signature as well as patient age and pathologic tumor (T), node (N), and metastasis (M) 
stages. Pathologic T, N, and M stages were binned into T1 vs. T >1, N0 vs. N>0, and M0 vs. M >0 groups 
to reduce the number of variables in each model and standardize across tumor types. All survival 
analyses were performed in R version 2.13.1 using the “survival” package (169, 170). 
BCR Restriction Index 
Expression levels for all BCR gene segments were calculated as described previously (1). 
Similarly, overall BCR expression and BCR diversity values were calculated according to previously 
described methods (1). To derive the BCR restriction index, glioblastoma and renal cell carcinoma 
samples were first excluded, as they show patterns of worse survival with B-cell infiltrates. To minimize 
the influence of outlier samples, a resampling approach was taken to obtaining RI scores within the set of 
non-GBM, non-renal samples (n = 2904). Thus, 1000 times, a random sample of 2/3 of the data set was 
identified and a Cox proportional hazards model was calculated for overall survival vs. the interaction of 
the BCR expression and BCR diversity values. This model was used to predict risk on the remaining 1/3 
of the data, and for each iteration the linear predictor values for this 1/3 of the data were recorded. The 
final RI values for the non-GBM, non-renal samples, then, were calculated as the mean of the linear 
predictor values across all samplings. This restriction index, then, while tied explicitly to overall survival in 
the set of 2904 non-GBM, non-renal samples, clearly highlights samples with high BCR expression and 
relatively low BCR diversity (i.e. BCR-restricted samples). Even though these BCR characteristics do not 
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predict favorable outcomes in GBM and renal cell carcinoma, RI values were calculated for these 
samples to generate predictions of how restricted the B-cell TIL populations were in those tumors. A Cox 
proportional model of all 2904 non-GBM, non-renal cell samples (which correlates very highly with the 
values obtained through the resampling method) was then calculated and used to predict risk on the GBM 
and renal cell carcinoma samples. The linear predictor values for these samples, which highlight high-
expression, low-diversity samples even though they are not associated with better survival in these tumor 
types, were used as restriction index values for these last two tumor types. This prediction schema, along 
with the coefficients of the model developed on the 2904 non-GBM, non-renal cell samples, is presented 
in Figure 3.6. 
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Results 
Signatures of Immune Infiltration are Coordinately Expressed in Human Cancer 
Increased expression of gene signatures representing TILs has been shown to be favorably 
prognostic in many tumor types, including breast, colorectal, ovarian, non-small cell lung cancer, and 
melanoma. To clarify the role of tumor-infiltrating immune cells, gene signatures associated with distinct 
immune cell types were evaluated in a diverse data set of 3485 tumors representing 12 distinct tumor 
types (see methods). Signatures were chosen that were previously published as corresponding to tumor-
infiltrating immune cells in at least one solid tumor type. Several gene signatures were used for each cell 
type studied (T-cells, CD8
+
 T-cells, B/plasma cells, and tumor-associated macrophages), which served to 
mitigate the effects of differences in gene list constituency and/or the technical effects seen when 
translating a microarray-derived gene list for application to our mRNA-seq data set. A heat map of a 
subset of these signatures across all 3485 samples ordered by tissue type and genomic subtype shows 
high expression across gene signatures in particular cancer types and subtypes (Figure 3.1). Immune 
signature expression is highest in the basal bladder, basal-like and HER2-enriched breast, 
immunoreactive ovarian, and immune melanoma subtypes, as well as in the head and neck squamous, 
clear cell renal cell, lung adenocarcinoma, squamous cell lung carcinoma tissue types (Figure 3.1). Within 
tissue types, immune signature expression varied widely by subtype. While only the ovarian 
immunoreactive and melanoma immune subtypes were defined with immune infiltration as a key feature, 
immune infiltration often segregated by tumor subtype. Similarly the LUAD-enriched, squamous, breast 
basal-like, and KIRC COCA (Cluster of Cluster Analysis genomic classification) subtypes show high 
expression of immune signatures. Signature scores across tissue types and COCA subtypes are 
summarized in Figure 3.2. Within and across all tumor types, all immune gene signatures that were tested 
showed very high correlations, with the average Pearson correlation > 0.63 for all tumor tissue of origin or 
COCA types (Figure 3.3). The lowest inter-signature correlation was among glioblastoma samples; all 
glioblastoma samples showed low expression of lymphocyte-related gene signatures and high expression 
of signatures related to macrophages and other myeloid-derived cell types. This is likely due to 
expression of characteristic macrophage genes both by TAMs and by microglia, which are prevalent in 
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many primary gliomas, while lymphocyte infiltration in glioblastoma is less common and less extensive 
when compared to other solid tumor types (171, 172). 
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Figure 3.3 Signatures of lymphocyte infiltration in breast tumors are highly correlated in A all 
samples and B-L within samples in each tissue type. 
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Signatures of Immune Infiltration are Prognostically Important in Diverse Human Cancers 
Univariate survival analyses for immune signature expression within tissue of origin groups or 
COCA genomically-defined subtypes are summarized in Tables 3.1-3.2 (hazard ratios are provided in 
Appendix 2, Supplementary Tables 1-2). Number of events and median follow-up times varied 
significantly between tumor types. Almost all immune signatures tested were prognostic in the set of all 
3485 samples. The breast, head and neck, lung adenocarcinoma, melanoma, and endometrial tumor 
types showed improved survival among patients with tumors scoring high for a variety of immune 
signatures. When samples were divided by COCA subtype rather than tissue of origin, the LUAD-
enriched, squamous, UCEC, and melanoma COCA subtypes showed improved survival with high 
immune signature expression for at least four signatures each. Signatures of lymphocyte invasion more 
consistently predicted overall survival; the lung adenocarcinoma, head and neck squamous, breast, and 
endometrial tumor types show consistent prognostic ability for lymphocyte signatures and a decreased 
association between survival and macrophage signatures. Interestingly, among clear cell renal cell 
carcinoma samples there was a strong association of B-cell signature expression with poorer survival, 
and no clear association with other immune signatures. Macrophage-related signatures were less 
commonly prognostic, and were associated with worse survival in the overall set and specifically within 
glioblastoma. Furthermore, gene signatures representing T-cell and B-cell TILs and macrophages were 
associated with worse survival within the GBM data set. 
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Multivariate survival analyses of immune signatures are summarized in Table 3.3. Signatures 
representing each of the immune cell classes investigated (B/plasma cells, T-cells, CD8
+
 T-cells, 
macrophages) were prognostic in the overall set when patient age, tumor tissue type, and pathologic 
tumor (T), node (N), and metastasis (M) status were included in the model. Separate multivariate models 
were tested for each tumor tissue type individually, again including patient age, immune signature, and 
pathologic T, N, and M status (Appendix 2, Supplementary Tables 3-10). For each of these sets of 
included variables, the results of multivariate modeling largely supported the results seen in the univariate 
survival models, with head and neck squamous cell carcinoma, lung adenocarcinoma, and melanoma 
showing consistent prognostic benefit for patients with high immune gene expression. Glioblastoma, 
ovarian and endometrial tumors were excluded from multivariate analyses within tissue types, as 
pathologic T, N, and M stages were not available for these tumor types. For tumor types representing 
more than one COCA subtype, separate multivariate models were also built including COCA subtype as a 
variable; this did not meaningfully change the prognostic value of immune signatures (data not shown). 
The results of the multivariate analyses reveal that immune invasion represents an independent predictor 
of survival across several tumor types even when accounting for the common pathologic features of those 
tumors. 
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Prognostic Immune Infiltrates are Associated with Reduced Tumor-infiltrating B-Cell Clonality 
Previous investigations of TIL infiltration have suggested that many tumors with prevalent TILs 
contain clonally restricted T- or B-cell infiltrates (46, 52, 118). These TIL infiltrates may potentially be 
targeting tumor antigens, which is consistent with results showing a prognostic benefit for TILs in these 
tumor types. As previously described, mRNA-seq data can be used to estimate relative clonal diversity of 
B-cell populations (1). Somatic hypermutation introduces many point mutations in the sequence of the B-
cell receptor (BCR) of B-cells undergoing the germinal center reaction. These point mutations, combined 
with the identity of the variable (V), diversity (D) , and joining (J) segments of the BCR, are likely unique to 
a B-cell clone within an individual. Different patterns of non-reference bases identified in mRNA-seq reads 
mapping to BCR V gene segments represent different B-cell clones, so enumerating those patterns 
across highly expressed V gene segments provides an estimate of clonal diversity in a B-cell population. 
Because this method relies on mutations generated by SHM, it cannot be readily applied to TCR segment 
reads.  For this analysis, BCR V gene segment expression and diversity values were calculated for all 
samples. Figure 3.4 illustrates BCR gene segment expression across all tissue types and COCA 
subtypes, highlighting the same tissue types identified by gene signature analysis. While BCR expression 
is able to distinguish certain samples and tumor types as high expressers of BCR segments, expression 
was high across multiple BCR gene segments in such samples. This could potentially represent 
ambiguity in unique alignment of mRNA-seq reads due to high sequence similarity between many BCR 
segments. Previous work by our group has shown that in breast and ovarian tumors, samples with 
prognostic B-cell infiltrates correspond to those tumors with high expression and relatively low diversity 
values. Figure 3.5 shows BCR expression and sequence diversity for all samples and demonstrates the 
existence of a high-expression, low-diversity group composed mainly of melanoma, basal-like breast, 
lung, and head and neck squamous tumors. To test the association of this phenotype with survival, a Cox 
proportional hazards model was built using BCR expression, diversity, and an interaction term between 
BCR expression and diversity (while training on overall survival). This yields a linear predictor that will be 
used as a “Restriction Index” (RI), where low RI values indicate BCR-restricted samples (versus samples 
appearing to contain a clonally diverse B-cell infiltrate). As shown in Figure 3.6, samples with low RI have 
high expression of BCR segments and relatively low BCR sequence diversity for their expression level. 
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The Cox proportional model containing BCR expression, diversity, and their interaction was tested by 
ANOVA against various B-cell gene signatures; the BCR model predicted outcome significantly better in 
all cases. Because the RI was developed through modeling overall survival, it is expected that this metric 
would outperform other signatures. Analysis of the RI on an independent test set is pending and will 
further clarify the prognostic association of this score. 
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Figure 3.4 Heatmap of BCR expression across tumors. A Unsupervised hierarchical 
clustering of expression of all BCR gene segments in all samples; column color bar indicates 
tissue type and row color bar indicates BCR segment type. B Unsupervised hierarchical 
clustering of average BCR gene segment expression by tissue type. C Unsupervised 
hierarchical clustering of average BCR gene segment expression by COCA subtype. 
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Figure 3.5 BCR V segment sequence diversity (by log10(effective number of species)) vs. BCR 
V segment expression (by log10(read counts)) for all samples, colored by A tissue type or B COCA 
subtype shows a distinct group of high expression, low diversity samples comprising mainly basal 
breast, melanoma, and lung cancer samples. 
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Figure 3.6 A Schema outlining the development of the Restriction Index (RI). B BCR V segment 
sequence diversity (by log10(effective number of species)) vs. BCR V segment expression (by 
log10(read counts)) for all samples, colored by the RI risk score. Low RI indicates lower risk in terms 
of overall survival. 
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Discussion 
Here we highlight several aspects of an effective, potentially antigen-driven immune response, as 
determined from mRNA-seq data, in diverse solid human tumor types. Patients with apparently beneficial 
tumor immune responses had high levels of immune signature expression for several cell types including 
cytotoxic and helper T-cells, B/plasma cells, and macrophages/monocytes. High expression of these 
immune signatures predicted survival across distinct tumor types. Furthermore, among these highly 
immune infiltrated tumors, a subset contained a highly expressed population of BCRs with low sequence 
diversity, which also predicted improved survival in these patients. Together, these findings highlight a 
subset of tumors among the squamous/basal bladder, basal-like and HER2-enriched breast, 
immunoreactive ovarian, and immune melanoma subtypes, as well as a subset of tumors among head 
and neck, lung adenocarcinoma, and lung squamous cell carcinoma, that appear to have a beneficial, 
antigen-directed immune response. 
Tumors in this data set were analyzed both by tissue of origin and genomic COCA subtype, as 
well as by genomic subtype defined within the tissue of origin. By considering each of these classification 
schemes, it is possible to identify classifications that are relevant for the role of immune infiltration in 
these tumor types. The squamous COCA subtype, for example, groups together some bladder, head and 
neck, and lung tumors with a common set of genomic features. This set of tumors is also consistently high 
for immune signature expression, and groups together tumors and tumor types with prognostic immune 
infiltrates. Similarly, the breast basal-like COCA subtype, which also shows some squamous-like genomic 
characteristics, also separates out breast tumors that often harbor prognostic immune infiltrates. The fact 
that these subtypes were defined comprehensively by global gene expression, protein levels, copy 
number miRNA, and DNA methylation demonstrates that these subtype-defining features may be 
responsible for the immunogenic phenotype shared among these tumors.  
Retrospective analyses in melanoma and bladder cancer treated with ipilumimab and 
MPDL3280A, respectively, have shown that high levels of pre-treatment CD8
+
 TILs correlate with 
response to immune checkpoint inhibitors in those tumor types (88, 105). The emerging picture from 
clinical trials and preclinical models of immune checkpoint inhibition is that a pre-treatment immune 
response within the tumor microenvironment is important for response to treatment. Thus, it is reasonable 
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to suppose that the tumor types and subtypes highlighted above as having high immune signature 
expression and restricted B-cell TIL infiltrates may also represent the groups in which immune checkpoint 
inhibition is most promising. 
Most investigations into the role of TILs in human tumors have been focused on T-cells. Many 
studies have shown that the presence of T-cell TILs is associated with response to immune checkpoint 
inhibition and survival in diverse tumor types (13, 88, 105, 173). Here, we demonstrate that in all tumor 
types analyzed in this work, B-cell gene expression, including expression of BCR gene segments, was 
highly correlated with the expression of T-cell genes. The high correlation of immune signature 
expression across distinct immune cell types illustrates that the tumor immune infiltrate is diverse and 
complex, and supports the idea of an important supportive role for B-cell TILs and some types of TAM in 
the anti-tumor immune response. Cox proportional hazards modeling of BCR expression and diversity 
demonstrates that BCR restriction adds significantly to the prognostic ability of the model beyond BCR 
expression or other B-cell gene expression (although this finding will need to be further validated in test 
sets of independent data). The additional prognostic value of BCR restriction indicates an important role 
for B-cell TILs in the anti-tumor immune response. It is unclear whether that role includes the production 
of anti-tumor antibodies to mediate cell killing, or if B-cell TILs primarily function by supporting an effective 
T-cell response. Previous work has shown that PD-1 blockade enhances the activation, proliferation, and 
cytokine production of human B-cells after TLR stimulation (151). Further work is needed to clarify the 
role of B-cell TILs in the clinical efficacy of immune checkpoint inhibition. 
Overall, for most of the tumor types tested, immune infiltrates portended an improved outcome; 
however, there were three tumor types which are exceptions to this rule. Thus, it should not be assumed 
that immune cells play a simple, one-dimensional role across all tumor anatomic sites. One notable tumor 
type in which immune signature expression consistently did not predict survival in this work was colorectal 
adenocarcinoma. There are many studies indicating a beneficial and prognostic role for TILs, including 
helper and cytotoxic T-cells and potentially Treg, in human colorectal cancer (174-176). The failure to 
detect these associations in this data set, we believe, has largely has to do with the lack of adequate 
follow-up data. In this data set, only 44 events were recorded among the 250 patients with colorectal 
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cancer. Similarly, poor survival data in breast and endometrial cancer limited survival predictions as well, 
resulting in inconsistent prognostic value among immune signatures. 
An interesting biological outlier tumor type in our results was renal cell carcinoma, which scored 
consistently high for expression of immune signatures. However, unlike other highly immune-infiltrated 
tumor types in this analysis, high expression of T-cell signatures did not predict good outcomes in renal 
cell carcinoma, and high expression of B-cell signatures consistently predicted poor prognosis. To 
examine the role of B-cells in renal cell carcinoma more carefully, we generated a restriction index score 
solely within this tumor type and found that it was almost precisely the opposite of the restriction index 
developed on other tumor types and applied to renal cell samples (r
2
 = 0.938, slope of line of best fit = -
3.44; data not shown). This suggests that it is specifically the presence of a clonally restricted B-cell 
infiltrate that predicts poor prognosis within renal cell carcinomas. Previous work has suggested that this 
tumor type may contain abundant Breg; a clinical trial was conducted in which the anti-CD20 monoclonal 
antibody Rituximab was used to deplete B-cells from renal cell tumors (86). The failure of that trial to 
show clinical benefit may have been largely due to the low CD20 expression of Breg and the resulting 
failure of Rituximab to affect that population (87). The presence of B-cell TILs associated with poor 
outcome in renal cell carcinoma could also be explained by other mechanisms: B-cell tolerization and 
anergy due to other immunoregulatory cell types likely plays a role. It is also possible that this association 
may be partly artifactual due to an association between TILs and higher tumor grade, which in turn 
predicts worse outcomes, in this tumor type. However, the successes of anti-PD-1 treatment and, earlier, 
of IL-2 therapy in renal cell carcinoma, shows that a beneficial immune response is possible in this tumor 
type. Thus, renal cell carcinoma remains an immunogenic tumor type in which further study is certainly 
needed. 
Lastly, glioblastoma multiforme also stood out within this analysis as a tumor type in which 
immune infiltration appears to predict worse outcomes. By univariate modeling, immune signatures 
representing several distinct tumor-infiltrating immune cell phenotypes predicted worse overall survival in 
the GBM tumor type. This result adds to the conflicting and generally unclear understanding of immune 
infiltration in gliomas. TIL and TAM infiltrates have frequently been observed in gliomas, and, as in our 
data, infiltrating macrophages and/or microglia often represent a large proportion of tumor immune 
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infiltrates in this tumor type (177, 178). However, the results of studies associating TILs and/or TAMs in 
human glioma with clinical outcome are mixed; studies have published associations between immune 
infiltration and either better or worse patient survival (179-182). The dominance of TAMs (and/or 
microglia) within the immune infiltrate of GBM is consistent with a negative clinical impact; these TAMs 
may represent M2 cells increasing angiogenesis and driving an inflammatory, pro-tumor 
microenvironment. However, due to a relative dearth of clinical data in this tumor type, this analysis, like 
others before it, is likely confounded by tumor grade and other clinical factors. Careful follow-up is 
certainly required in this tumor type, and must take into account not only immune cell prevalence but 
precise immune cell phenotype, tumor subtype, grade, and location, and other clinical factors. 
In summary, for most solid epithelial tumor types, the presence of one immune cell type was 
highly correlated with the presence of other immune cell types, and the presence of these multiple 
immune cell types predicted a more favorable outcome. Analysis of the potential clonal restriction seen 
within these TILs suggests that in tumors with heavy immune infiltration, B-cell clonal restriction has 
occurred or is occurring. In addition, B-cell TIL clonal restriction as determined by BCR diversity 
measures suggests that clonal restriction, as a genomic feature, is also highly prognostic. However, not 
all tumor types show these common features, with the most notable outliers being GBM and clear cell 
renal cell carcinoma, where high immune infiltration may portend a worse outcome. Thus, measures of 
immune cell phenotypes, BCR (and likely TCR) diversity, and tissue type or subtype are needed to 
correctly interpret, and likely act upon, these characteristics of the tumor microenvironment. 
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CHAPTER 4 – MOUSE MODELS OF BREAST CANCER ELICIT CONSISTENT, SUBTYPE SPECIFIC 
IgH AND TCRβ CLONAL RESTRICTION 
 
Introduction 
Tumor infiltrating lymphocytes (TILs) have long been understood to be associated with some 
breast tumors (11, 12, 21). However, the role of TILs in affecting the biology of the tumor 
microenvironment or the clinical course of the tumor is still not fully understood. Several studies have 
shown that TILs in breast tumors are largely T-cells, and of those, cytotoxic CD8
+
 T-cells have been 
observed to dominate in some breast tumors (19, 120). Tumor-infiltrating B-cells and plasma cells are 
more poorly understood, but have also been observed in breast tumors by immunohistochemistry, 
immunofluorescence, and gene expression signatures representing B-cells (15, 35, 41). Tumor-infiltrating 
immune cells of various phenotypes have been reported to affect prognosis and response to treatment. 
The presence of CD8
+
 TILs and proportion of CD8
+
 cells among TILs in breast tumors are a positive 
prognostic feature (13, 14, 21). Regulatory T-cells (Treg), which dampen cytotoxic T-cell responses, are a 
predictor of poor survival in breast cancer (30, 33). The role of B-cell lineage TILs (B-cells, plasmablasts, 
plasma cells – in this work, these will be referred to as “B-cell TILs”) has been addressed less thoroughly, 
but the presence of B-cell TILs by immunohistochemistry has been shown to be a positive prognostic 
feature (15, 16, 38-41). These findings, taken together, paint a picture of a B-cell and CD8
+
 T-cell-
mediated anti-tumor immune response that is partially successful and thereby able to improve survival. 
This anti-tumor immune response may then be opposed by regulatory immune cells in the tumor 
microenvironment including Treg, myeloid-derived suppressor cells, and M2 macrophages (30, 59, 72, 77). 
The tumor may contribute to immune evasion by recruiting these immunosuppressive cell types, as well 
as by expression of PDL-1 and/or PDL-2, downregulation of MHC genes, and release of 
immunoregulatory cytokines (183-185). Work in melanoma and other immunogenic tumor types has 
shown that manipulation of the tumor immune response, especially through immune checkpoint inhibition, 
can contribute substantially to effective cancer treatment. 
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Human breast cancer is a heterogeneous group of diseases; breast tumors vary widely by 
morphology, clinical course, metastatic potential, and response to therapy. Analysis of genome-wide gene 
expression patterns has identified five genomic subtypes of breast cancer: luminal A, luminal B, HER2-
enriched, basal-like, and claudin-low, as well as a normal-like group (2-6). These genomic subtypes also 
vary by their abundance of TILs, with basal-like, HER2-enriched, and claudin-low tumors commonly being 
densely infiltrated by TILs. Of these, evidence of beneficial immune infiltration that impacts survival is 
strongest among basal-like tumors (14, 16). It has been shown that both B- and T-cell TILs predict better 
outcomes among patients with basal-like breast cancer (10, 41). There is evidence that HER2-enriched 
tumors may also benefit from TIL infiltration (1, 186). The claudin-low subtype remains promising as a 
highly immunogenic tumor type, but so far no association between TILs and prognosis in the claudin-low 
subtype has been shown (4, 187). 
The association between TILs and survival in breast cancer suggests the presence of a partially 
successful anti-tumor response. That this association is also closely tied to tumor subtype in turn 
suggests that specific subtypes may present tumor antigens, neoantigens, and/or overexpressed 
immunogenic proteins that may be targeted by the adaptive immune system. If such subtype-specific 
tumor antigens do exist, those antigens represent a target for treatment, either by drugs targeting those 
molecules or by immunotherapy to potentiate the existing anti-tumor immune response. Tumor 
microenvironments in which antigen-directed TIL responses are occurring may be distinguished from 
nonspecific inflammation by clonal restriction in the TIL pool. TILs able to bind tumor antigens will expand 
clonally, either in the tumor-draining lymph nodes or potentially in the tumor microenvironment (188, 189). 
B-cell clones may also undergo the germinal center reaction in the lymph node, which includes antibody 
class-switching and the process of somatic hypermutation (SHM), in which mutations to the B-cell 
receptor (BCR) generate new B-cell clones potentially able to bind antigen with greater affinity/avidity 
(128, 129). The microenvironment of a tumor presenting one or more tumor antigens, then, is expected to 
be enriched for these antigen-targeting TIL clones (and will thus be clonally restricted). 
Due to the immense diversity generated through V(D)J recombination and, in B-cells, SHM, 
lymphocyte clones within an individual bear unique B-cell receptor or T-cell receptor (TCR) sequences. 
Spectratyping, a technique in which BCR or TCR sequences are amplified by pcr from cDNA and run on 
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a gel to compare the distribution of sequence lengths, offered initial insight into the comparative clonal 
diversity of lymphocyte populations (190). Recently, advances in next-generation sequencing have made 
it possible to sequence the entire BCR or TCR mRNA repertoires present in a sample and thus learn 
much more about the nature of that lymphocyte population (114, 191-196). This technique, known as 
immune receptor repertoire profiling, has been used to estimate clonal abundance and diversity in many 
settings, such as HIV infection and rheumatoid arthritis (197, 198). Immune repertoire sequencing in 
cancer holds promise for discriminating tumors that have antigen-directed TIL responses and potentially 
for identifying those antigens. Here, we present an interrogation of the immune repertoire in mouse 
models of breast cancer representing distinct breast cancer subtypes. By analyzing the TIL and 
peripheral blood T- and B-cell repertoires in these mouse models, we gain insight into the usefulness of 
these models for immunotherapy and potentially into the role of TILs in the human breast tumor subtypes 
they represent. 
  
쐀ҩ
66 
 
Methods 
Sample Preparation 
Five different genetically engineered mouse model tumor lines were used for these studies: three 
models derived from p53
-/-
 mice (T11, 2225, and 2250), the basal-like C3-TAg line, and one from the 
MMTV-NEU model (3, 199-202). For all of the mouse models excluding NT2 and vaccinated NT2 mice, 
animals were sacrificed when the tumor reached approximately 1cm
3
 in volume, as determined by caliper 
measurement. Tumor cell transplantation for the T11, 2225, and 2250 models was carried out as in 
Herschkowitz, et al. (3). For NT2 mice, tumors were obtained on day 21 after tumor cell injection. Tumor 
cell injection and viral particle (VRP) neu protein vaccination of NT2 mice was carried out as in Burgents, 
et al.(203). The tumor and spleen were obtained from each mouse, and single-cell suspensions were 
prepared from spleens as previously published in Riddle, et al. (204). These cells were then labeled with 
monoclonal antibodies for CD4 (clone CK1.5, eBioscience), CD8 (clone 53-6.7, eBioscience), and CD19 
(1D3, BD Pharmingen) and CD4
+
, CD8
+
, and CD19
+
 populations were isolated via fluorescence-activated 
cell sorting (FACS). Total RNA was isolated from each of the three sorted spleen populations as well as 
from whole tumor using the Qiagen RNeasy mini kit. The overall schema for sample preparation is 
presented as Figure 4.1. 
Repertoire Amplification and Sequencing 
Reverse transcription and amplicon-rescue multiplex PCR was performed using mouse 
immunoglobulin heavy chain and TCR beta chain primers from iRepertoire (Huntsville, AL), using the 
Invitrogen SuperScript III polymerase kit for reverse transcription and PCR stage 1, and the Qiagen 
HotStar HiFidelity polymerase for PCR stage 2 (196). Amplicon libraries were sequenced on the Illumina 
MiSeq (2 x 150bp for TCR libraries, 2 x 250 bp for BCR libraries). A total of 104 libraries were sequenced, 
representing 32 libraries from the tumor and 72 libraries from the spleen for the 24 animals tested. 
Clonotype Identification 
After trimming adaptor sequences, clonotype identification was performed using the IMGT 
High/V-QUEST web tool (IMGT®, the international ImMunoGeneTics information system® 
http://www.imgt.org (founder and director: Marie-Paule Lefranc, Montpellier, France)) (141-147). Unique 
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clonotypes for either TCR or BCR were determined as specific V and J alleles and the full amino acid 
sequence of the complementarity-determining region 3 (CDR3). 
Statistical Analysis 
The Shannon entropy index was used for calculation of relative diversity of tumor and spleen 
repertoires. TCRβ tumor clonotypes were assigned to either CD4
+
 or CD8
+
 phenotype pools by 
interrogating the paired CD4
+
 and CD8
+
 splenic populations for the given individual. If a clonotype was 
present in both the CD4
+
 and CD8
+
 splenic populations, it was assigned to one population only if one 
splenic population had at least ten times as many reads supporting the clonotype as the other population, 
and the population with fewer reads supporting the clonotype had fewer than 20 reads supporting the 
clonotype. 
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Results 
T- and B-Cell Clonal Restriction in Mouse Models of Breast Cancer 
To assess the T- and B-cell TIL repertoires, five mouse models of breast cancer representing 
distinct breast cancer subtypes were employed. Three models, the 2225, 2250, and T11 models, 
represent basal-like, luminal, and claudin-low tumors, respectively, that arose stochastically from p53
-/-
 
BALB/c mammary tissue implanted in p53 wild type BALB/c mice (3, 199, 200). These models have the 
advantage of sharing a common genetic background and initiating event (i.e. TP53 loss). The C3-TAg 
model is a spontaneous GEMM of basal-like breast cancer, and the NT2 model is an implantable model 
derived from the MMTV-NEU mouse model, which is a model of HER2
+
 human breast tumors (201, 202). 
From the NT2 model, we prepared untreated tumors as well as tumors treated with a rat neu VRP vaccine 
that has previously been shown to inhibit tumor growth in this model (203). The vaccinated NT2 mice 
serve as a positive control in which there is a known, effective anti-tumor immune response against a 
single, known antigen. In each of these models, tumors and spleens were harvested from four individuals. 
Splenic lymphocytes, which serve as a surrogate for the peripheral blood lymphocyte pool, were sorted 
into CD4
+
, CD8
+
, and CD19
+
 populations by FACS. RNA from these sorted splenic populations, as well as 
from whole tumor, was used for IgH and TCRβ repertoire amplification and next-generation sequencing. 
The overall sample preparation schema is outlined as Figure 4.1. 
In sequencing pcr-amplified tumor immune repertoires, it is critical to keep the number of pcr 
cycles consistent between samples in order to properly control for, and minimize, amplification bias. This 
has the unfortunate consequence of preventing tumors with very low lymphocyte presence from being 
amplified sufficiently for downstream sequencing. Here we present data only from tumor repertoires with 
adequate IgH or TCRβ RNA content to sequence effectively. Samples with very low TIL content could not 
be analyzed, but these tumors are also unlikely to harbor clonal anti-tumor TIL populations. Read counts 
for each sequenced repertoire are included in Figure 4.2. 
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Figure 4.1 Schema for sample preparation for mouse IgH 
and TCRβ matched tumor and spleen repertoire sequencing. 
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Figure 4.2 Number of reads identified as belonging to a recombined 
A TCRβ or B IgH molecule in all sequenced repertoire libraries. 
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Using the IMGT/HighV-QUEST tool, sequences from spleen and tumor repertoires were grouped 
into clonotypes, representing sequences sharing common alleles for V and J gene segments and a 
common amino acid sequence of the highly variable, antigen-binding CDR3 (IMGT, the international 
ImMunoGeneTics information system® http://www.imgt.org; founder and director: Marie-Paule Lefranc, 
Montpellier, France) (142-147). To assess the clonal diversity of lymphocyte populations, the prevalence 
of each clonotype in a population can be used to calculate a diversity score using the Shannon entropy 
metric. Figure 4.3 shows the Shannon entropy value for each IgH and TCRβ repertoire sequenced. All 
splenic populations were highly diverse and had an equivalent level of diversity. In contrast, tumor IgH 
and TCRβ repertoires were nearly universally more restricted than their matched splenic lymphocyte 
repertoires. Furthermore, tumor repertoire diversity varied highly between mouse models. The TCRβ 
repertoires of the T11 and vaccinated NT2 models were consistently less diverse, and this result is 
replicated in the IgH repertoires from the same individuals. The similar level of diversity among tumor 
repertoires between individuals suggests a distinct, consistent tumor immune microenvironment produced 
reproducibly by each tumor model. 
Dominant TIL clones are detectable from peripheral repertoires 
To pursue the peripheral background level of dominant tumor IgH and TCRβ clonotypes, the 
matched spleen repertoires for each mouse were investigated for the prevalence of abundant tumor 
clonotypes. Figure 4.4 displays the relative abundance of dominant TCRβ tumor clones in tumor and 
matched spleen samples for all individuals. In most individuals, the most abundant tumor clonotypes were 
detected in the matched spleen repertoire. Moreover, dominant tumor clonotypes were present at higher 
levels in the spleen than clonotypes detected at low levels within the tumor. However, dominant tumor 
clonotypes were not dominant in the spleen; splenic repertoires were highly diverse and lacked any 
dominant clones in all individuals. This reinforces the idea that tumor repertoires are truly clonally 
restricted, with lymphocyte clones present at very low levels in the peripheral blood despite representing 
a large proportion of total TIL content. 
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Figure 4.3 Shannon entropy of clonotype distributions within tumor and spleen A 
IgH (left: spleen, right: tumor) and B TCRβ (left: spleen CD4
+
, middle: spleen CD8
+
, 
right: tumor) repertoires show comparatively low diversity within tumor repertoires and 
consistent clonal restriction within the T11 and vaccinated NT2 models. 
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Figure 4.4 Abundance of splenic (either CD4
+
 or CD8
+
 populations) TCRβ 
clonotypes, ordered by their abundance in matched tumor samples, shows 
enrichment of spleen repertoires for dominant tumor clonotypes in all mouse models. 
Only the first 20,000 clonotypes are shown for each mouse model to show detail. 
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Exact clonotype sharing is rare in between individuals 
The number of reads representing clonotypes discovered in one, two, three, or all four individuals 
for each model is shown in Figure 4.5. Exact clonotype sharing between individuals was rare overall, but 
the NT2 vaccinated tumors and the T11 tumors showed distributions skewed toward greater sharing 
between individuals. The 2250 model may also exhibit significant shared TCRβ clonotypes, although this 
analysis was limited due to low abundance of TCRβ sequence in 2250 tumors resulting in less sequence 
data for that model. 
T-Cell TIL CD4+/CD8+ Ratio is distinct between mouse models of breast cancer 
The phenotypic subsets represented by T-cell TILs are critical to understanding the tumor 
immune repertoire. CD8
+
 TILs may be cytotoxic effector cells that are actively killing tumor cells that bear 
tumor antigens. While CD4
+
 cells may represent Th1 T helper cells aiding the anti-tumor response, they 
may also be regulatory T-cells (Treg), actively opposing the anti-tumor immune response through a variety 
of mechanisms. Because many TCRβ tumor clonotypes can be identified in the spleen, splenic CD4
+
 and 
CD8
+
 repertoires were interrogated for the presence of tumor clonotypes. Since it is very unlikely for the 
same TCRβ clonotype to appear in both the CD4
+
 and CD8
+
 populations in an individual, identification of 
a tumor clonotype in either sorted population effectively identifies that clonotype as belonging to either a 
CD4
+
 or CD8
+
 TIL. Figure 4.6 shows that the distribution of clonotypes mapped to either the CD4
+
 or 
CD8
+
 subset is largely consistent between individuals in a mouse model and distinct between models. 
The ratio of sequences mapped to CD8
+
 and CD4
+
 subsets clearly distinguishes the T11 and vaccinated 
NT2 models as harboring T-cell TIL populations enriched for CD8
+
 cells. Along with the evidence that 
these models have clonally restricted T- and B-cell TIL repertoires, these data highlight the T11 and 
vaccinated NT2 models as those with potentially effective and antigen-directed anti-tumor immune 
responses. 
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Figure 4.5 Number of A TCRβ or B IgH clonotype reads, grouped by 
the number of tumors tumors in which they were identified (within each 
mouse model). The T11 and vaccinated NT2 models show skewing 
toward clonotypes shared among more individuals for both TCRβ and IgH. 
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Figure 4.6 A CD8
+
/CD4
+
 ratio of tumor reads in clonotypes identified in matched 
splenic CD4
+
 or CD8
+
 populations; the T11, vaccinated NT2, and potentially C3-TAg 
models show increased  CD8
+
/CD4
+
 ratios. B-G Tumor clonotypes by rank 
abundance, colored by the matched spleen population(s) also containing those 
clonotypes; the T11 and vaccinated NT2 models show a skewing toward the CD8
+
 
population among dominant clonotypes. 
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Dominant TIL clones across individuals share sequence characteristics between individuals 
The presence of a replicated, potentially antigen-directed anti-tumor immune response in 
particular mouse models of breast cancer makes it appealing to identify sequences involved in binding 
tumor antigens. In the three p53
-/-
 BALB/c models and the NT2 model, and to a lesser extent in the 
C(3)Tag model, tumor antigens presented are likely the same between individuals in the same mouse 
model. Thus, clonal restriction should bear evidence of directed evolution towards clones able to bind the 
same small set of protein sequences. To pursue this idea, dominant tumor IgH and TCRβ clones across 
individuals in each mouse model were compared in order to discover sequence characteristics potentially 
involved in tumor antigen binding. In the T11 model, three clear B-cell clonotype groups appeared, each 
representing sequences from all four individuals (Figure 4.7). Similarly, in the vaccinated NT2 model, 
three TCRβ sequence groups appeared, each containing sequences from all three individuals. Consistent 
with previous data, these two models were the only models to show clear clonotype groups. The repeated 
similarity of the T11 model to the “positive control” vaccinated NT2 model highlights the T11 as a 
potentially useful model for understanding naturally occurring anti-tumor host immune responses in 
general. 
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Figure 4.7 Among clonotypes identified with greater total abundance in tumor samples than 
spleen samples within a mouse model and with at least ten supporting reads in each tumor in which 
the clonotype was identified, similar clonotype groups appear in A vaccinated NT2 TCRβ and B T11 
IgH tumor populations. Heat maps indicate abundance of each clonotype in all tumor and spleen 
samples in the relevant mouse model. 
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Discussion 
In this work, we explore the tumor TCRβ and IgH repertoire in mouse models of different breast 
cancer subtypes, and identify some aspects of the tumor immune repertoire associated with an antigen-
driven TIL response in B and T-cell TILs. The T11 and vaccinated NT2 models showed consistently 
restricted TCRβ and IgH tumor repertoires with dominant tumor clones not overrepresented in matched 
spleen repertoires, high CD8
+
/CD4
+
 TCRβ clonotype ratios, and the emergence of common clonotype 
sequence characteristics, particularly in the antigen-binding CDR3. These models, then, are promising as 
models for breast tumors presenting one or more tumor antigens. Work aimed at detecting tumor 
antigens bound by dominant TIL clones in these models, with the vaccinated NT2 as a positive control, 
may be instrumental in advancing strategies for antigen detection from human tumors. 
In human breast tumors, the majority of evidence for beneficial or potentially antigen-directed 
immune responses points toward the basal-like subtype (1, 14, 16). However, the basal-like 2225 model 
did not show strong evidence of tumor antigens, while the claudin-low T11 model did. Human claudin-low 
breast tumors are often heavily infiltrated by TILs, but previous work investigating the prognostic role of 
lymphocyte gene signatures in breast cancer showed consistent prognostic value for TIL-expressed 
genes in basal-like and HER2-enriched tumors but not for patients with claudin-low breast tumors (1). It is 
important to consider that claudin-low tumors represent the least frequent breast tumor type, and survival 
analyses may have been limited by small patient numbers. However, the lack of prognostic value of TILs 
may also be due to a highly immunosuppressive tumor microenvironment in claudin-low tumors 
preventing an effective anti-tumor TIL response. If this is the case, it highlights claudin-low tumors as a 
tumor type especially likely to benefit from immune checkpoint inhibitors aimed at reversing this 
immunosuppression. Further analysis of human claudin-low tumors is needed to determine whether the 
lack of prognostic association of immune cells in that subtype is due to the makeup of the immune 
infiltrate (e.g. a high proportion of immunosuppressive cells), tumor-intrinsic characteristics (fewer 
genomic derangements leading to a dearth of recognized antigens), a lack of statistical power due to low 
sample numbers, or some other factor. 
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The T11 and vaccinated NT2 models, which appear most likely to harbor an antigen-directed anti-
tumor TIL response, also show enrichment for CD8
+
 T-cell TIL clonotypes. This supports the idea of an 
anti-tumor response, as CD8
+
 TILs have been shown to predict better outcomes in several human tumors 
types and direct tumor cell killing has been hypothesized as a primary method by which the host immune 
system attacks tumors (13, 22, 176, 205). However, the data presented here show clonal restriction in 
both the CD4
+
 and CD8
+
 T-cell TIL pools. There is evidence to suggest that CD4
+
 Th1 helper T-cells are 
present in tumor infiltrates and contribute to anti-tumor responses (28). However, it is unknown what 
portion of the CD4
+
 pool observed here is composed of immunosuppressive Treg. None of these mouse 
models experience spontaneous tumor regression, so abundance of Treg among the CD4
+
 pool, among 
other immunosuppressive cell types in the tumor microenvironment, is likely. Further investigation into 
clonal restriction and abundance of Treg in these mouse models, and in different subtypes of human 
breast cancer, is needed to clarify the question of the TIL response in breast cancer. 
Among the models that may harbor an antigen-directed TIL response, several groups of 
clonotypes shared across individuals and sharing sequence characteristics were identified. Notably, 
analysis of shared clonotypes did not result in clonotypes reproduced exactly and highly dominant in all 
individuals within a model. This represents an additional challenge in antigen detection – because 
antigen-binding clonotypes arise through directed evolution and the potential sequence diversity of the 
TCR or BCR is so large, it is reasonable to expect different solutions to the problem of antigen binding to 
arise in different individuals, even when the set of bound antigens may be the same. The identification of 
clonotype “families” sharing V and/or J alleles and having similar length and amino acid sequence of the 
CDR3 is consistent with the picture of clones binding a common antigen but arising in different 
individuals. Furthermore, because antigen binding depends on the final three-dimensional conformation 
of the antigen-binding surface of the TCR or BCR molecule, even highly divergent CDR3 sequences may 
not reflect different antigen targets. Computational modeling of paired heavy and light BCR or α and β 
TCR chains may be best able to resolve this question, and would greatly enhance our understanding of 
adaptive immune repertoires. 
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In summary, subtype-specific mouse models of breast cancer elicited consistent and predictable 
T-cell and B-cell responses in the tumor microenvironment, and these responses were interrogated to 
show clonally restricted, potentially antigen-driven T-cell and B-cell responses in specific mouse models. 
Dominant tumor clonotypes were reliably detected in matched spleen repertoires, but were not dominant 
in those spleen repertoires, underscoring the notion of a tumor-directed response. These dominant tumor 
clonotypes, when they arose in likely immunogenic mouse models, showed sequence similarity between 
individual mice of those mouse models. Classification of tumor TCRβ clonotypes as representing CD4
+
 or 
CD8
+
 T-cell TILs demonstrated that the mouse models with the greatest evidence of an antigen-directed 
anti-tumor immune response were also enriched for CD8
+
 T-cell TILs, especially among dominant clones. 
In general, these findings describe some of the important TIL repertoire characteristics expected of 
antigen-driven anti-tumor immune responses. Specifically, this work also supports the use of the T11 
mouse model of claudin-low breast cancer as an immunogenic tumor model that may present tumor 
neoantigens. To the extent that this mouse model mirrors human breast cancer, these results also 
highlight the claudin-low subtype as an immunogenic tumor type that may be effectively treated by 
immune checkpoint inhibition or other immunotherapeutic strategies. 
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CHAPTER 5 – DISCUSSION 
 In this work, we first examine the nature and role of TILs specifically within breast and ovarian 
cancer. In Chapter 2, we highlight several important aspects of the TIL response in subtypes of these two 
tumor types and pursue how much can be discovered about the B-cell TIL repertoire from short-read 
mRNA-seq data. We show that for a diverse population of tumors within these two tumor types, gene 
signatures representing specific tumor-infiltrating immune cell types can be derived through unsupervised 
hierarchical clustering. Moreover, using these and other TIL gene expression signatures, we demonstrate 
that gene expression for these signatures is highly coordinately expressed across cell types represented 
and highly correlated to tumor subtype. We develop methods for assessing BCR expression and BCR 
diversity, as well as the extent of SHM, of a B-cell population, from short-read mRNA-seq data alone. 
These methods then distinguish a population of basal-like and HER2-enriched breast and 
immunoreactive ovarian tumors with high BCR expression and relatively low BCR diversity, 
corresponding to a potentially antigen-directed B-cell TIL response. Importantly, this work highlights B-cell 
TILs as a potentially important aspect of the anti-tumor immune response. 
 The work presented in Chapter 3 expands on the genomic analyses in Chapter 2, first of all by 
applying them to a data set representing 12 diverse solid tumor types. Gene expression analyses of T-
cell, B-cell, and macrophage signatures support a paradigm in which most solid epithelial tumor types 
with prevalent TIL infiltrates are able to elicit an anti-tumor adaptive immune response associated with 
favorable outcomes in those patients. However, tumor types are also identified that may behave 
differently; the TIL infiltrates of glioblastoma multiforme and clear cell renal cell carcinoma are distinct 
from TILs in other tumor types in our analyses, and warrant further study. Using the wide array of tumors 
in tumor types wherein TIL infiltrates correlate with better survival, we develop a single-value Restriction 
Index to identify clonally restricted B-cell TIL responses. This Restriction Index, while it must still be 
validated in independent test data sets, may be valuable for inferring B-cell population characteristics 
where only short-read RNA-seq data exist. 
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 Chapter 4 represents a more detailed analysis of TIL repertoires in breast cancer, using mouse 
models and long-read immune repertoire sequencing to answer questions currently beyond the scope of 
what may be inferred from short-read mRNA-seq data. The results of this analysis provide evidence for 
TIL-specific clonal dominance, recurrent TCR and BCR sequence characteristics, and enrichment of 
CD8
+
 T-cell TILs in breast tumors likely eliciting an anti-tumor immune response. By comparing these 
mouse models to mice treated with an effective tumor vaccine presenting a known peptide, we are able to 
distinguish the T11 mouse model of claudin-low breast cancer as having many of the same TIL repertoire 
characteristics associated with an antigen-directed response. This mouse model may shed light on the 
biology of human tumors with anti-tumor TIL responses, not least by providing a model to test immune 
checkpoint inhibitors. Furthermore, as long-read immune repertoire sequencing data become available in 
human tumors and/or as repertoire inference methods are developed for short-read data, the repertoire 
characteristics identified here may guide analyses of TIL repertoires in diverse settings. 
 Taken together, the work presented in this dissertation aims at both defining the nature of the 
anti-tumor TIL response and advancing the level of detail about TIL responses which can be inferred from 
sequencing data. By identifying tumor types and subtypes likely to harbor antigen-directed anti-tumor 
TILs and enumerating the genomic characteristics of such anti-tumor TIL populations, we pursue the 
question of which tumors may elicit an anti-tumor immune response. This question is imminently valuable 
as we now have access to drugs able to manipulate immunosuppression and potentiate anti-tumor 
immune responses. Future work applying the analytic framework presented here to new data sets, 
including data from tumors treated with immune checkpoint inhibitors, may further advance our 
understanding of the role of the immune system in human tumor biology. 
The recent success of immunotherapy in several tumor types has reinvigorated interest in the 
anti-tumor immune response. Through immune checkpoint inhibition, durable disease response can be 
achieved in diverse cancer types including melanoma, lung, bladder, and renal cell carcinoma (94-96, 
101-103). Furthermore, immune-based cancer therapies are accompanied by a different spectrum of 
adverse effects, and in some cases are much less morbid than traditional chemotherapy. Initial trials of 
tumor immunotherapy have been restricted to small numbers of patients, generally with extensively pre-
treated tumors. However, success in these initial trials has generated momentum that is leading to larger 
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trials and inevitably raises the critical question of which patients can benefit from immunotherapy as a 
cancer treatment. Initial trials have focused on tumor types like renal cell carcinoma and melanoma, in 
which earlier immunotherapies like IL-2 treatment have shown clinical benefit (206, 207). But immune 
checkpoint inhibition is a more targeted and, so far, more effective tool for cancer treatment, and may 
have efficacy beyond these historically immunogenic tumor types. Thus, a central question in cancer 
treatment is the identification of patients and tumors likely to benefit from tumor immunotherapy. 
 The identification of genomic subtypes has contributed powerfully to our understanding of human 
cancer. Early identification of tumor subtypes in breast cancer, as defined by global patterns of gene 
expression, has drastically changed the way we think about the group of diseases collectively labeled as 
breast cancer. With the advent of The Cancer Genome Atlas, unprecedented volumes of genomic data 
have become available for many tumor types, and this in turn has led to the identification of genomic 
subtypes in tumor types and the fragmentation of previously monolithic diseases into multiple distinct 
tumor entities (159). If we are to believe that the tumor immune infiltrate is largely determined by 
characteristics of the infiltrated tumor, then a more nuanced understanding of the genome-wide behavior 
of diverse tumor types ought to help greatly in our prediction of immunogenic, and potentially immune-
treatable, tumors. Indeed, the work shown here makes a strong case that the prevalence of immune 
infiltration is strongly divided across tumor type and subtype lines. In the example of breast cancer, for 
example, the basal-like and HER2-enriched subtypes are associated with a prevalent immune infiltrate of 
diverse cell types, and this infiltrate is associated with improved survival specifically within those 
subtypes. Expanding this analysis to a wider range of tumor types highlights new tumor types and 
subtypes with dense, potentially beneficial, immune infiltrates. 
 The use of genomic subtypes in predicting responders to immunotherapy is promising, but there 
are still problems in this approach that must be worked out. Some of the more recently-defined genomic 
subtypes may describe the biology of the tumor microenvironment, but fail to identify tumor-intrinsic 
characteristics that strongly correlate with subtype assignment. The immunomodulatory ovarian cancer 
subtype and immune melanoma subtype are two of the most prominently immunogenic tumor types, and 
patients with tumors of these subtypes may benefit from immunotherapy. However, these subtypes 
highlight the fact that in some ways our current understanding of immunogenic cancer subtypes falls short 
배ҭ
85 
 
of what is needed: if the immune infiltrate is in some way responding to characteristics of the tumor, we 
need a more thorough understanding of what those specific characteristics are. These tumor-intrinsic 
characteristics, then, may further our understanding of what makes some tumors more immunogenic than 
others. 
 While it is possible that in some tumor types, the immune infiltrate may depend largely upon 
tumor chemokine release, angiogenesis and hypoxia, or tumor necrosis, the explanation that is most 
promising and most likely is that tumor-associated antigens are presented by some tumors. The identity 
and diversity of these antigens would be expected to vary by subtype, and where the antigens could be 
targeted, an effective tumor immune response would lead to better survival: this is consistent with results 
in this work and elsewhere. Even more encouraging are results from immunotherapy; in melanoma, 
response to ipilumumab correlated with number of mutations, and in non-small cell lung cancer, smoking 
history correlated with response to pembrolizumab (81, 208). Both of these examples highlight mutational 
burden as a predictor of a productive immune response, which is reasonable since a greater number of 
mutations would increase the chance of a recognizable mutant epitope being presented to the host 
immune system. Other genomic derangements are also attractive candidates for the production of tumor-
associated antigens, including translocations producing fusion genes, overexpressed tumor genes 
causing misfolded protein aggregates, mutations leading to dysfunctional chaperone proteins (such as 
heat shock proteins), and the so-called cancer-testis antigens. 
Overall, this work and others present a general framework for tumor immune infiltration in which 
mutations and other genomic insults incurred during oncogenesis then lead to the presentation of mutant 
epitopes, which are recognized by the host immune system and lead to dense immune infiltrates in the 
tumor microenvironment. In order to survive this immune response, tumor immunoediting occurs and a 
highly immunosuppressive milieu is cultivated around the tumor through altered antigen presentation, 
upregulation of immunoregulatory molecules such as PDL-1, and recruitment of immunosuppressive cell 
types including Treg, Breg, M2 TAMs, and MDSCs. Increased pre-treatment TIL count predicts response to 
ipilumumab in melanoma, underscoring the notion that patients likely to respond to immune checkpoint 
inhibition are already engaged in a dynamic balance between immunosuppression and an anti-tumor 
immune response involving diverse cell types.  
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Successful patient targeting for tumor immunotherapy, then, may initially progress by selecting 
patients who appear to already have an anti-tumor immune response. Pinpointing the most sensitive, 
specific, and cost-effective technique for this will certainly require extensive biomarker analysis in clinical 
trials largely yet to be performed. However, we can imagine that a combination of assays tumor biopsies, 
yielding prevalence estimates for CD8
+
 TILs, Treg, B-cell TILs, and myeloid lineage cells, would go a long 
way towards identifying potential responders. As high throughput sequencing becomes less expensive 
and more widely available, mRNA-seq from tumor biopsies would permit a much more thorough analysis 
of the immune infiltrate, which could be informed by studies such as those presented here. Where high-
throughput sequencing is available, estimates of TIL clonality (currently only for B-cells, although TCR 
reconstruction and clonality estimates may soon be feasible) would be expected to improve these 
predictions. Wider use and study of immune checkpoint inhibitors through targeting patients with an 
existing anti-tumor immune response would allow for further study of the more critical question of what 
antibodies and antigens, specifically, are involved in the successful tumor immune response.  
The truly central unsolved question of tumor immunology is the identity of tumor-associated 
antigens eliciting the observed immune responses (and, similarly, the identities of the TCR and BCR 
clonotypes best able to bind these antigens and elicit tumor cell killing). Long read sequencing of TIL 
receptor repertoires, such as is presented here in mouse models of breast cancer, is beginning to 
address this question. Wide application of this method in human tumors could lead to the association of 
specific TCR or BCR sequence characteristics with survival or response to therapy, or to specific 
mutations that may serve as tumor antigens. Paired long read sequencing of heavy and light chain BCR 
or α and β chain TCR would allow for three-dimensional modeling and indeed in vitro production of any 
promising receptor sequences. These full TCR or BCR sequences could be used for in vitro or in silico 
binding assays against tumor lysate, mutant tumor peptides, or human peptide arrays to hunt for specific 
targetable epitopes. Finally, as more long read sequencing of TCR and BCR repertoires becomes 
available, it may be possible to devise and validate a procedure for inferring the sequences of dominant 
TCR or BCR clonotypes from short read mRNA-seq data. If and when this becomes feasible, repositories 
of tumor genomic information such as TCGA may provide fertile ground for the association of recurrent 
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TIL clonotypes with tumor characteristics that have long evaded identification due to constraints of power 
and methodology. 
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APPENDIX 1: GENE SIGNATURES 
 
Signature 
Name B_Cell_cluster 
Cell Type B-Cells 
 
EntrezGene 
ID 
HUGO 
name 
 
3512 IGJ 
 
9834 KIAA0125 
 
608 TNFRSF17 
 
83416 FCRL5 
 
5450 POU2AF1 
 
973 CD79A 
 
96610 BMS1P20 
 
8755 ADAM6 
 
389643 NUGGC 
 
150365 MEI1 
 
974 CD79B 
 
5079 PAX5 
 
2208 FCER2 
 
79368 FCRL2 
 
643 CXCR5 
 
930 CD19 
 
84824 FCRLA 
 
640 BLK 
 
115350 FCRL1 
 
931 MS4A1 
 
1269 CNR2 
 
55024 BANK1 
 
23495 TNFRSF13B 
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Signature 
Name T_Cell_cluster 
Cell Type T-Cells 
 
EntrezGene 
ID 
HUGO 
name 
EntrezGene 
ID 
HUGO 
name 
EntrezGene 
ID 
HUGO 
name 
 
100188949 LINC00426 5790 PTPRCAP 5551 PRF1 
 
8530 CST7 374403 TBC1D10C 962 CD48 
 
9806 SPOCK2 10663 CXCR6 154075 SAMD3 
 
2672 GFI1 4063 LY9 917 CD3G 
 
497189 TIFAB 9744 ACAP1 7535 ZAP70 
 
140947 C5orf20 27240 SIT1 22914 KLRK1 
 
5133 PDCD1 201633 TIGIT 283897 C16orf54 
 
11184 MAP4K1 3932 LCK 923 CD6 
 
9051 PSTPIP1 55423 SIRPG 5579 PRKCB 
 
11151 CORO1A 919 CD247 8698 S1PR4 
 
11262 SP140 84174 SLA2 8320 EOMES 
 
115352 FCRL3 3702 ITK 387357 THEMIS 
 
29851 ICOS 10225 CD96 356 FASLG 
 
1493 CTLA4 4068 SH2D1A 120425 AMICA1 
 
4283 CXCL9 921 CD5 3718 JAK3 
 
56253 CRTAM 916 CD3E 26279 PLA2G2D 
 
9840 TESPA1 914 CD2 4049 LTA 
 
729230 CCR2 915 CD3D 924 CD7 
 
959 CD40LG 2833 CXCR3 1043 CD52 
 
952 CD38 114836 SLAMF6 3004 GZMM 
 
57823 SLAMF7 3561 IL2RG 27040 LAT 
 
3662 IRF4 53347 UBASH3A 
  
 
54900 LAX1 6504 SLAMF1 
  
 
387751 GVINP1 149628 PYHIN1 
  
 
84636 GPR174 939 CD27 
  
 
256380 SCML4 50852 TRAT1 
  
 
151888 BTLA 3001 GZMA 
  
 
925 CD8A 30009 TBX21 
  
 
3003 GZMK 5778 PTPN7 
  
 
29909 GPR171 6352 CCL5 
  
 
128611 ZNF831 4818 NKG7 
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Signature 
Name CD8_cluster 
Cell Type cytotoxic T-cells 
 
EntrezGene 
ID 
HUGO 
name 
EntrezGene 
ID 
HUGO 
name 
 
256380 SCML4 915 CD3D 
 
151888 BTLA 2833 CXCR3 
 
925 CD8A 114836 SLAMF6 
 
3003 GZMK 3561 IL2RG 
 
29909 GPR171 53347 UBASH3A 
 
128611 ZNF831 6504 SLAMF1 
 
5790 PTPRCAP 149628 PYHIN1 
 
374403 TBC1D10C 939 CD27 
 
10663 CXCR6 3001 GZMA 
 
4063 LY9 30009 TBX21 
 
9744 ACAP1 5778 PTPN7 
 
27240 SIT1 6352 CCL5 
 
201633 TIGIT 4818 NKG7 
 
3932 LCK 5551 PRF1 
 
55423 SIRPG 962 CD48 
 
919 CD247 154075 SAMD3 
 
84174 SLA2 917 CD3G 
 
3702 ITK 7535 ZAP70 
 
10225 CD96 22914 KLRK1 
 
4068 SH2D1A 283897 C16orf54 
 
921 CD5 923 CD6 
 
916 CD3E 5579 PRKCB 
 
914 CD2 8698 S1PR4 
 
  
쯐ҩ
91 
 
Signature 
Name MacTh1_cluster 
Cell Type Helper/Th1 cells & macrophages 
 
EntrezGene 
ID 
HUGO 
name 
EntrezGene 
ID 
HUGO 
name 
EntrezGene 
ID 
HUGO 
name 
 
26191 PTPN22 84433 CARD11 1234 CCR5 
 
5330 PLCB2 64231 MS4A6A 6693 SPN 
 
50856 CLEC4A 64098 PARVG 64333 ARHGAP9 
 
3111 HLA-DOA 8477 GPR65 10859 LILRB1 
 
752 FMNL1 80231 CXorf21 11006 LILRB4 
 
117289 TAGAP 3594 IL12RB1 2207 FCER1G 
 
5552 SRGN 286336 FAM78A 9056 SLC7A7 
 
1436 CSF1R 221472 FGD2 3903 LAIR1 
 
945 CD33 6404 SELPLG 84868 HAVCR2 
 
713 C1QB 951 CD37 7805 LAPTM5 
 
714 C1QC 3059 HCLS1 942 CD86 
 
712 C1QA 7454 WAS 23533 PIK3R5 
 
1520 CTSS 4689 NCF4 139716 GAB3 
 
146722 CD300LF 3689 ITGB2 64926 RASAL3 
 
3394 IRF8 83706 FERMT3 147138 TMC8 
 
388325 SCIMP 6688 SPI1 89857 KLHL6 
 
4332 MNDA 4542 MYO1F 54518 APBB1IP 
 
313 AOAH 27128 CYTH4 6503 SLA 
 
57705 WDFY4 79626 TNFAIP8L2 3635 INPP5D 
 
8832 CD84 199 AIF1 126364 LRRC25 
 
22797 TFEC 7940 LST1 27180 SIGLEC9 
 
1536 CYBB 124460 SNX20 27036 SIGLEC7 
 
5294 PIK3CG 695 BTK 968 CD68 
 
11309 SLCO2B1 3937 LCP2 3687 ITGAX 
 
3113 HLA-DPA1 5788 PTPRC 55803 ADAP2 
 
3115 HLA-DPB1 2124 EVI2B 719 C3AR1 
 
3122 HLA-DRA 3071 NCKAP1L 2123 EVI2A 
 
3109 HLA-DMB 963 CD53 7456 WIPF1 
 
3108 HLA-DMA 5341 PLEK 10875 FGL2 
 
972 CD74 920 CD4 10261 IGSF6 
 
64092 SAMSN1 54440 SASH3 10288 LILRB2 
 
219972 MPEG1 3587 IL10RA 51411 BIN2 
 
7133 TNFRSF1B 1794 DOCK2 89790 SIGLEC10 
 
9938 ARHGAP25 2533 FYB 51311 TLR8 
 
257106 ARHGAP30 10320 IKZF1 6039 RNASE6 
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Signature 
Name CD68_cluster 
Cell Type 
Macrophages/Monocytes/myeloid-derived 
cells 
 
EntrezGene ID HUGO name 
 
126364 LRRC25 
 
27180 SIGLEC9 
 
27036 SIGLEC7 
 
968 CD68 
 
3687 ITGAX 
 
55803 ADAP2 
 
719 C3AR1 
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APPENDIX 2: SURVIVAL ANALYSES 
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Supplementary Table 3 Multivariate Cox proportional p values for immune gene signature 
expression versus overall survival in BLCA. Each row indicates one multivariate model 
including age, pathologic T, N, and M, and one immune signature. NS indicates non-
significant p values (p ≥ 0.05). Superscript indicates origin of gene signature (1=Fan, et al. 
2011; 2=Rody, et al. 2011; 3=Schmidt, et al. 2008; 4=Iglesia, et al. 2014, 5=Beck, et al. 2009, 
6=Bindea, et al. 2013). Immune signature p values marked with † indicate high signature 
expression is associated with poor survival. 
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Supplementary Table 4 Multivariate Cox proportional p values for immune gene signature 
expression versus overall survival in BRCA. Each row indicates one multivariate model 
including age, pathologic T, N, and M, and one immune signature. NS indicates non-
significant p values (p ≥ 0.05). Superscript indicates origin of gene signature (1=Fan, et al. 
2011; 2=Rody, et al. 2011; 3=Schmidt, et al. 2008; 4=Iglesia, et al. 2014, 5=Beck, et al. 2009, 
6=Bindea, et al. 2013). Immune signature p values marked with † indicate high signature 
expression is associated with poor survival. 
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Supplementary Table 5 Multivariate Cox proportional p values for immune gene signature 
expression versus overall survival in CRC. Each row indicates one multivariate model 
including age, pathologic T, N, and M, and one immune signature. NS indicates non-
significant p values (p ≥ 0.05). Superscript indicates origin of gene signature (1=Fan, et al. 
2011; 2=Rody, et al. 2011; 3=Schmidt, et al. 2008; 4=Iglesia, et al. 2014, 5=Beck, et al. 2009, 
6=Bindea, et al. 2013). Immune signature p values marked with † indicate high signature 
expression is associated with poor survival. 
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Supplementary Table 6 Multivariate Cox proportional p values for immune gene signature 
expression versus overall survival in HNSC. Each row indicates one multivariate model 
including age, pathologic T, N, and M, and one immune signature. NS indicates non-
significant p values (p ≥ 0.05). Superscript indicates origin of gene signature (1=Fan, et al. 
2011; 2=Rody, et al. 2011; 3=Schmidt, et al. 2008; 4=Iglesia, et al. 2014, 5=Beck, et al. 2009, 
6=Bindea, et al. 2013). Immune signature p values marked with † indicate high signature 
expression is associated with poor survival. 
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Supplementary Table 7 Multivariate Cox proportional p values for immune gene signature 
expression versus overall survival in KIRC. Each row indicates one multivariate model 
including age, pathologic T, N, and M, and one immune signature. NS indicates non-
significant p values (p ≥ 0.05). Superscript indicates origin of gene signature (1=Fan, et al. 
2011; 2=Rody, et al. 2011; 3=Schmidt, et al. 2008; 4=Iglesia, et al. 2014, 5=Beck, et al. 2009, 
6=Bindea, et al. 2013). Immune signature p values marked with † indicate high signature 
expression is associated with poor survival. 
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Supplementary Table 8 Multivariate Cox proportional p values for immune gene signature 
expression versus overall survival in LUAD. Each row indicates one multivariate model 
including age, pathologic T, N, and M, and one immune signature. NS indicates non-
significant p values (p ≥ 0.05). Superscript indicates origin of gene signature (1=Fan, et al. 
2011; 2=Rody, et al. 2011; 3=Schmidt, et al. 2008; 4=Iglesia, et al. 2014, 5=Beck, et al. 2009, 
6=Bindea, et al. 2013). Immune signature p values marked with † indicate high signature 
expression is associated with poor survival. 
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Supplementary Table 9 Multivariate Cox proportional p values for immune gene signature 
expression versus overall survival in LUSC. Each row indicates one multivariate model 
including age, pathologic T, N, and M, and one immune signature. NS indicates non-
significant p values (p ≥ 0.05). Superscript indicates origin of gene signature (1=Fan, et al. 
2011; 2=Rody, et al. 2011; 3=Schmidt, et al. 2008; 4=Iglesia, et al. 2014, 5=Beck, et al. 2009, 
6=Bindea, et al. 2013). Immune signature p values marked with † indicate high signature 
expression is associated with poor survival. 
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Supplementary Table 10 Multivariate Cox proportional p values for immune gene 
signature expression versus overall survival in SKCM. Each row indicates one multivariate 
model including age, pathologic T, N, and M, and one immune signature. NS indicates non-
significant p values (p ≥ 0.05). Superscript indicates origin of gene signature (1=Fan, et al. 
2011; 2=Rody, et al. 2011; 3=Schmidt, et al. 2008; 4=Iglesia, et al. 2014, 5=Beck, et al. 2009, 
6=Bindea, et al. 2013). Immune signature p values marked with † indicate high signature 
expression is associated with poor survival. 
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